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ABSTRACT
Fenofibrate  is  a  poorly  water-soluble  oral  antihyperlipidemic  agent  belonging  to
fibrate class, with problems of variable bioavailability and bio-inequivalence related
to  its  poor  water-solubility.  This  work  investigated  the  possibility  of  developing
Fenofibrate  tablets  by  WOWTAB  technology  (with  out  water) allowing  fast,
reproducible,  and  complete  drug  dissolution,  by  using  solid  dispersion  of  drug.
Among  various  carriers  used  HPMC  3cps  is  forming  a  stable  solid  dispersion.
Solubility studies were performed to investigate the drug-carrier interactions by both
solvent  evaporation  and  melt  fusion  method.  DSC, X-ray powder  diffraction,  and
FTIR studies were used to characterize the solid state of solid dispersions. The tablets
were  prepared  by  WOW  technology  by  conventional  granulation  and  tableting
                                                                                                                                          
  
methods  employing  low  and  high-moldability  saccharides  (Mannitol,  sorbitol
respectively)  to  have  desired  properties  of  rapid  disintegration  and  hardness.  The
prepared tablets were evaluated thickness, uniformity of weight, content uniformity,
hardness,  friability,  In  vitro  disintegration  time.  The  tablets  were  subjected  to
moisture treatment to lower the DT. After moisture exposure tablets are evaluated for
uniformity of weight, hardness, friability, In vitro disintegration time and In vitro drug
release.  The  tablets  apart  from  fulfilling  all  official  and  other  specifications,  the
Fenofibrate dissolution profile from the newly developed tablets was clearly better
than those from various conventional tablets of the same drug dosage. The stability
studies conducted as per ICH guidelines at 40° and 75% RH showed insignificant loss
in drug content and on physical evaluations at the end of six months.
Key  terms:  Solid  dispersion,  WOWTAB  technology,  Saccharides,  Moisture
treatment
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I. INTRODUCTION
Solid oral drug delivery is the simplest and easiest way of administering drugs. These
dosage forms have many advantages over other types of oral dosage forms. Therefore, most
of the New Chemical Entities (NCE) under development are intended to be used as a solid
dosage forms that originate an effective and reproducible in vivo plasma concentration after
oral administration. 
The  aqueous  solubility  of  a  drug  is  one  of  the  key  physical
properties that affect both its ADME profile and ‘screen ability’ in High
Throughput  Screening  (HTS).  Solubility  is  the  characteristic  physical  property
referring  to  ‘the  ability  of  a  given  substance,  the  solute,  to  dissolve  in  a  solvent’.
Enhancement of oral bioavailability of poorly water soluble drugs remains one of the most
challenging aspects of drug development. Solubility and dissolution are the rate determining
steps in drug absorption. 
Table 1: Solubility Terms (According to USP)
Biopharmaceutical Classification System categorized poorly soluble and highly permeable 
drugs under class II. Nearly 40 % of the drug molecules that have been discovered are 
lipophilic in nature.
1
Definition
Parts of solvent required for
one part of solute
Very Soluble <1
Freely Soluble 1-10
Soluble 10-30
Sparingly Soluble 30-100
Slightly Soluble 100-1000
Very Slightly Soluble 1000-10,000
Insoluble > 10,000
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Table 2:  Biopharmaceutical Classification System (According to BCS
classification by FDA)
Class Description
Class I Highly soluble, highly permeable
Class II Poorly soluble, highly permeable
Class III Highly soluble, Poorly permeable
Class IV Poorly soluble, Poorly permeable
Figure 1: Graphical representation of Biopharmaceutical Classification System 
1.1 Factors Affecting Solubility
Several factors affect solubility of a drug. The following are the factors that affect solubility
(K Patidar et al., 2011). 
1. Particle Size
2. Temperature
3. Pressure
4. Nature of the solute and solvent
5. Molecular size
6. Polarity
7. Polymorphs
2
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1.2 Approaches for increasing solubility (Bell LN et al.,1995).
A) Formulation approach
a) Reduction in particle size by
i) Micronization technique
ii) Nanosuspension formulation.
b) Modification of the crystal habits
c) Complexation of drug as
i) Inclusion complex
ii) Ion exchange complex
d) Solubilization and surfactants
i) Micronization
ii) Micelles formation
iii) Formulation of self-emulsifying drug delivery systems
e) Formation of solid dispersions with water soluble carriers.
B) Chemical modification
a) Salt formation
b) Prodrug formation
c) Polar group incorporation
3
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1.3 INTRODUCTION TO SOLID DISPERSIONS
Solid  dispersions  are  one  of  the  most  promising  strategies  to  improve  the  oral
bioavailability of poorly water soluble drugs. By reducing drug particle size to the absolute
minimum, and hence improving drug wettability,  solubility increases hence bioavailability
may be significantly improved. They are usually presented as amorphous products, mainly
obtained  by  two  major  different  methods,  melting  and  solvent  evaporation(Abu  T.M.
Serajuddin., 1999).
Figure 2: A schematic representation of the bioavailability enhancement of a poorly 
soluble drug by solid dispersion compared with conventional tablet or capsule.
4
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Figure 3: The classification of solid dispersions (Teófilo Vasconcelos et al., 2007).
Dispersion of the drug as very fine particles  will  increase the surface area
available for dissolution. According to the classical Noyes-Whitney equation this will
increase  the  dissolution  rate.  Particle  size  reduction  may  go  to  the  nano-scale.
However, even this size reduction will not lead to concentrations above the maximum
solubility of the drug in the intestinal fluids. Alternatively, solid dispersions can be
used to increase the dissolution rate of poorly soluble drugs, and they have proven to
increase  the  amount  of  dissolved  drug  at  the  absorption  site  sometimes  to
supersaturated  concentrations  and  consequently  improve  the  bioavailability.  Solid
dispersions are investigated in many studies because they are highly versatile in their
application.  They  can  form  the  basis  of  products  applied  for  various  routes  of
administration and for various dosage forms, including the most popular dosage form:
the tablet 
5
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Table 3: Types of solid dispersions (D.J. van Drooge, 2006).(34)
Solid Dispersion Type Matrix Drug No. of
Phases
I
Eutectics Crystalline Crystalline particles 2
II Amorphous
Precipitations in
crystalline matrix
Crystalline
Amorphous clusters
2
III Solid solutions
Continuous solid
solutions
Crystalline Molecularly
dispersed
1
Discontinuous solid
solutions
Crystalline Molecularly
dispersed
2
Substitutional solid
solutions
Crystalline Molecularly
dispersed
1 or 2
Interstitial solid
solutions
Crystalline Molecularly
dispersed
2
IV Glass suspension Amorphous Crystalline particles 2
V Glass suspension Amorphous Amorphous clusters 2
VI Glass solution Amorphous Molecularly
dispersed
1
1.3.1 Advantages of solid dispersion (D.J. van Drooge, 2006)(34)
1. Particles with reduced particle size
6
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Molecular dispersions, as solid dispersions, represent the last  state on particle size
reduction, and after carrier dissolution the drug is molecularly dispersed in the dissolution
medium. Solid dispersions apply this principle to drug release by creating a mixture of a
poorly water soluble drug and highly soluble carriers, a high surface area is formed, resulting
in an increased dissolution rate and, consequently, improved bioavailability. 
2. Particles with improved wettability
A  strong  contribution  to  the  enhancement  of  drug  solubility  is  related  to  the
improvement of drug wettability of solid dispersions.
3. Particles with higher porosity
Particles in solid dispersions have been found to have a higher degree of porosity. The
increase in porosity also depends on the carrier properties;  for instance,  solid dispersions
containing linear polymers produce larger and more porous particles than those containing
reticular polymers and, therefore, result in a higher dissolution rate. The increased porosity of
solid dispersion particles also hastens the drug release profile.
4. Drugs in amorphous state
Poorly water  soluble crystalline drugs,  when in the amorphous state tend to  have
higher solubility. The enhancement of drug release can usually be achieved using the drug in
its amorphous state, because no energy is required to break up the crystal lattice during the
dissolution process. In solid dispersions, drugs are presented as supersaturated solutions after
system  dissolution,  and  it  is  speculated  that,  if  drugs  precipitate,  it  is  as  a  metastable
polymorphic form with higher solubility than the most stable crystal form.
For drugs with low crystal energy (low melting temperature or heat of fusion), the
amorphous  composition  is  primarily  dictated  by  the  difference  in  melting  temperature
between drug and carrier. For drugs with high crystal energy, higher amorphous compositions
can be obtained by choosing carriers, which exhibit specific interactions with them.
7
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Table 4: Materials used as carriers for Solid Dispersions (Ingel U.S et al., 2011).(39)
Materials Examples
Sugars Dextrose, Sucrose, Galactose, Sorbitol, Maltose, Mannitol, 
Xylitol, Lactose.
Acids Citric acid, succinic acid
Polymeric materials Povidone (PVP), (Poly ethylene glycol) (PEG), Hydroxy 
propyl methyl cellulose, methyl cellulose, Hydroxy ethyl 
cellulose, cyclodextrins, Hydroxy propyl cellulose, Pectin, 
Gal.
Insoluble or enteric 
polymers
Hydroxy propyl -methyl cellulose phthalate, Eudragit L- 
100, Eudragit S- 100, Eudragit RL, Eudragit RS.
Surfactants Polyoxyethylene stearate, Renex, Poloxamer 188, Texafor 
AIP, Deoxycholic acid, Tweens, Spans.
Miscellaneous Pentaerythritol, Pentaerythrityl tetra acetate, urea, urethane, 
Hydroxyalkylxanthins.
1.3.2 METHODS OF PREPARATION OF SOLID DISPERSIONS
Various preparation methods for solid dispersions have been reported in literature.
8
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Figure 4: Manufacturing processes used to produce solid dispersions (Gaurav Tiwari et
al., 2009).(24)
Solvent evaporation
In this method, the physical mixture of the drug and carrier is dissolved in a common
solvent, which is evaporated until a clear, solvent free film is left. The film is further dried to
constant  weight.  The main advantage  of  the solvent  method is  thermal  decomposition of
drugs or carriers can be prevented because of the relatively low temperatures required for the
evaporation of organic solvents. 
Melting/fusion method
The melting or fusion method involves the preparation of physical mixture of a drug
and a water soluble carrier and heating it directly until it melted. The melted mixture is then
solidified rapidly in  an ice-bath under  vigorous stirring.  The final  solid  mass is  crushed,
pulverized and sieved. Appropriately this has undergone many modifications in pouring the
homogenous melt in the form of a thin layer onto a ferrite plate or a stainless steel plate and
cooled by flowing air or water on the opposite side of the plate. In addition, a super-saturation
of a solute or drug in a system can often be obtained by quenching the melt rapidly from a
high temperature. Under such conditions, the solute molecule is arrested in the solvent matrix
by the  instantaneous  solidification  process.  The quenching technique  gives  a  much finer
dispersion of crystallites when used for simple eutectic mixtures.
Advantages of melting methods
9
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1) Economic
2) Solvent less process
Disadvantages of melting methods
1) This method is not suitable for the drug or carrier unstable at fusion temperature or 
evaporates at higher temperature.
2) Solidification temperature may affect crystallization rate and hardness of the dispersion.
3) Irregular crystallization owing to the presence of a miscibility gap on the phase diagram 
for a given drug-carrier system.
In  1961, Sekiguchi and Obi  formed eutectic mixtures  of  drugs with water-soluble
carriers  by  melting  their  physical  mixtures.  This  was  a  significant  advance  in  the
development of solid dispersion systems. 
Solvent-melting method (melt evaporation)
This  method  involves  dissolving  the  drug  in  a  suitable  organic  solvent  and  then
incorporating the solution directly into the molten carrier, which is then evaporated until a
clear, solvent free film is left. The film is further dried to constant weight. This method is
particularly  useful  for  drugs  having high  melting  points  or  which  are  thermolabile.  This
technique possesses unique advantages of both the fusion and solvent evaporation methods.
From a practical standpoint, it is only limited to drugs with a low therapeutic dose e.g. below
50 mg. 
Melt Agglomeration Process
This technique has been used to prepare Solid Dispersion wherein the binder acts as a
carrier.  In  addition,  SD(s)  are prepared either  by heating binder,  drug and excipient  to a
temperature above the melting point  of  the binder  (melt-  in procedure)  or  by spraying a
dispersion of drug in molten binder on the heated excipient (spray-on procedure) by using a
high shear mixer. A rotary processor has been shown to be alternative equipment for melt
agglomeration because of easier control of the temperature and because higher binder content
can be incorporated in the agglomerates. The effect of binder type, method of manufacturing
and particle size are critical parameters in preparation of SD(s) by melt agglomeration. It has
been investigated that the melt in procedure gives a higher dissolution rates than the spray-on
10
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procedure  with  PEG  3000,  poloxamer  188  and  gelucire  50/13  attributed  to  immersion
mechanism of  agglomerate formation and growth.  In  addition the melt  in procedure also
results in homogenous distribution of drug in agglomerate.
Lyophilization Technique
Freeze-drying  involves  transfer  of  heat  and  mass  to  and  from the  product  under
preparation. This technique was proposed as an alternative technique to solvent evaporation.
Lyophilization has been thought of a molecular mixing technique where the drug and carrier
are co dissolved in a common solvent, frozen and sublimed to obtain a lyophilized molecular
dispersion.
Melt extrusion
Melt extrusion is a new method for producing solid dispersions. Special equipment is
needed  to  develop  the  dosage  form  from  solid  dispersions,  which  limits  the  use  of  the
extrusion method. Forster et al. report the use of melt extrusion to prepare glass solutions of
poorly water-soluble drugs with hydrophilic excipients. It is claimed that the method is an
improvement to existing formulation methods such as spray-drying and co-melting because it
uses smaller quantities of drug, reduces particle size and speeds up the formulation process. 
Electrospinning Method
The electrospinning technology used in the polymer industry combines solid solution/
dispersion technology with nanotechnology. In this process, a liquid stream of a drug/polymer
solution is subjected to a potential between 5 and 30 kV. When electrical forces overcome the
surface  tension  of  the  drug/polymer  solution  at  the  air  interface,  fibers  of  submicron
diameters are formed. As the solvent evaporates,  the formed fibers can be collected on a
screen to give a nonwoven fabric, or they can be collected on a spinning mandrel. The fiber
diameters  depend  on  surface  tension,  dielectric  constant,  feeding  rate,  and  electric  field
strength.  This  technique  has  tremendous  potential  for  the  preparation  of  nanofibres  and
controlling the release of biomedicine, as it is simplest and the cheapest this technique can be
utilized for the preparation of solid dispersions in future.
11
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Dropping solution Method:
The  dropping  method,  developed  by  Ulrich  et  al.  (1997)  to  facilitate  the
crystallization of different chemicals, is a new procedure for producing round particles from
melted solid dispersions. This technique may overcome some of the difficulties inherent in
the other methods.
For laboratory-scale preparation, a solid dispersion of a melted drug-carrier mixture is
pipetted and then dropped onto a plate, where it solidifies into round particles. The size and
shape of the particles can be influenced by factors such as the viscosity of the melt and the
size of the pipette. Because viscosity is highly temperature-dependent, it is very important to
adjust  the temperature  so  that  when the  melt  is  dropped onto  the  plate  it  solidifies  to  a
spherical shape. The use of carriers that solidify at room temperature may aid the dropping
process. The dropping method not only simplifies the manufacturing process, but also gives a
higher  dissolution  rate.  It  does  not  use  organic  solvents  and,  therefore,  has  none  of  the
problems  associated  with solvent  evaporation.  The method also  avoids  the  pulverization,
sifting  and  compressibility  difficulties  encountered  with  the  other  melt  methods.
Disadvantages of the dropping method are that only thermostable drugs can be used and the
physical instability of solid dispersions is a further challenge.
Alternative strategies
Spraying on sugar beads using a fluidized bed coating system
The approach involves a fluidized bed coating system, wherein a drug-carrier solution
is sprayed onto the granular surface of excipients or sugar spheres to produce either granules
ready for table ting or drug-coated pellets for encapsulation in one step. The method has been
applied for both controlled- and immediate-release solid dispersions.
Hot-melt extrusion
Melt extrusion was used as a manufacturing tool in the pharmaceutical industry as
early as 1971. 20 Since the turn of the century, many studies have been conducted on this
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process for the preparation of solid dispersion. It  has been reported that melt extrusion of
miscible components results in amorphous solid solution formation, whereas extrusion of an
immiscible component  leads  to  amorphous drug dispersed in  crystalline excipient. 21 The
process has been useful  in the preparation of solid dispersions in a single step.  Hot-melt
extrusion method is used in the preparation of various dosage forms in the pharmaceutical
industry such as preparation of sustained-release pellets.
Direct capsule filling
The filling of semisolid materials into hard gelatin capsules as melts, which solidify at
room temperature, was first done in 1978. Laboratory-scale semiautomatic equipment and
large-scale manufacturing equipment for direct  capsule filling are commercially available.
Direct  filling  of  hard  gelatin  capsules  with  the  liquid  melt  of  solid  dispersions  avoids
grinding-induced changes in the crystallinity of the drug. This molten dispersion forms a
solid plug inside the capsule on cooling to room temperature, reducing cross contamination
and operator exposure in a dust-free environment, better fill weight and content uniformity
was obtained than with the powder-fill technique. However, PEG was not a suitable carrier
for the direct capsule-filling method as the water-soluble carrier dissolved more rapidly than
the drug, resulting in drug-rich layers formed over the surface of dissolving plugs,  which
prevented further dissolution of the drug.   A surfactant must be mixed with the carrier to
avoid  formation  of  a  drug-rich  surface  layer  (e.g.  polysorbate  80  with  PEG,
phosphatidylcholine with PEG). The temperature of the molten solution should not exceed
~700C because it might compromise the hard-gelatin capsule shell.
Surface-active carriers
A surface-active carrier may be preferable in almost all cases for the solid dispersion
of  poorly  water-soluble  drugs.  The  surface-active  and  self-emulsifying  carriers  for  solid
dispersion of poorly water-soluble drugs have been of great interest in recent years.
Two of the important  surface-active carriers are Gelucire 44/14 and Vitamin E R-
alpha-tocopheryl  polyethylene  glycol  1000  succinate  (TPGS).  Gelucire  44/14  (Gattefosse
Corp,  Gennevilliers,  France)  has  commonly  been  used  in  solid  dispersion  for  the
bioavailability enhancement of drugs. 
13
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A commonly used surfactant, Polysorbate 80, when mixed with solid PEG, has also
been reported to be an alternative surface-active carrier.  Polysorbate 80 is  liquid at  room
temperature; it  forms a solid matrix when it is mixed with a PEG because it  incorporates
within the amorphous regions of PEG solid structure.
Initial formulation development studies can be conducted by filling hot solutions or
dispersions into hard-gelatin capsule shells manually by using pipettes or by using laboratory-
scale semiautomatic equipment.
Supercritical fluid technology(SCF)
It  has  been  known  for  more  than  a  century  that  supercritical  fluids  (SCFs)  can
dissolve nonvolatile solvents, with the critical point of carbon dioxide, the most widely used
supercritical fluid. SCF technology offers tremendous potential, as it is safe, environmentally
friendly,  and  economical.  The  low operating conditions  (temperature  and  pressure)  make
SCFs attractive for pharmaceutical research.
In the pharmaceutical field, the SCF technology was industrially applied in the early
1980s;  the  applications  included  the  purification  of  surfactants  and  pharmaceuticals,
fractionation of polymeric materials and chemical reactions and polymerizations. In the same
period, interest in using SCFs for precipitation and crystallization processes was developing
for pharmaceutical materials. A SCF exists as a single phase above its critical temperature
(Tc) and pressure (Pc). SCFs have properties useful to product processing because they are
intermediate  between  those  of  pure  liquid  and  gas  (i.e.,  liquid-like  density,  gas-like
compressibility  and  viscosity  and  higher  diffusivity than  liquids).  Moreover,  the  density,
transport properties (such as viscosity and diffusivity), and other physical properties (such as
dielectric  constant  and  polarity)  vary  considerably  with  small  changes  in  operating
temperature, pressure, or both around the critical points. Hence, it is possible to fine-tune a
unique combination of  properties  necessary for  a  desired  application (Patidar  Kalpana et
al.,2010). 
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The limitations of this technology have been a drawback for the commercialization of solid 
dispersions.35 
The limitations include:
1. Laborious and expensive methods of preparation,
2. Reproducibility of physicochemical characteristics,
3. Difficulty in incorporating into formulation of dosage forms,
4. Scale-up of manufacturing process, and
5. Stability of the drug and vehicle.
1.3.3 TECHNIQUES TO EXPLORE MOLECULAR INTERACTIONS AND 
BEHAVIOR (Gaurav Tiwari et al.,2009).(24)
Drug –carrier miscibility
 Hot stage microscopy
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 DSC (Conventional modulated)
 pXRD (Conventional and variable temp)
 NMR 1H Spin lattice relaxation time
Drug carrier interactions
 FT-IR spectroscopy
 Raman spectroscopy
 Solid state NMR
Physical Structure
 Scanning electron microscopy
 Surface area analysis
Surface properties
 Dynamic vapor sorption
 Inverse gas chromatography
 Atomic force microscopy
 Raman microscopy
Amorphous content
 Polarized light optical microscopy
 Hot stage microscopy
 Humidity stage microscopy
 DSC (MTDSC)
 ITC
 pXRD
Stability
 Humidity studies
 Isothermal calorimetry
 DSC (glass transition temperature(Tg), Temperature recrystallization)
 Dynamic vapor sorption
 Saturated solubility studies
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Dissolution enhancement
 Dissolution
 Intrinsic dissolution
 Dynamic solubility
 Dissolution in bio-relevant media
17
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1.4 DISEASE PROFILE
Hypercholesterolemia
Hypercholesterolemia (literally:  high blood cholesterol) is the presence of high levels of
cholesterol in the blood. It is not a disease but a metabolic derangement that can be secondary
to many diseases and can contribute to many forms of disease, most notably cardiovascular
disease.  It  is  closely related to the terms "hyperlipidemia" (elevated levels of  lipids) and
"hyperlipoproteinemia" (elevated levels of lipoproteins).
Causes:
Diet  -Cholesterol levels can increase by a high intake of saturated fat, excess calories and
dietary  cholesterol.  Also,  HDL levels  can  decrease  and  LDL level  increase  if  person  is
overweight. 
Heredity -  The way individual’s body makes and handles cholesterol  can be a matter of
genes, as well as diet and lifestyle.
Medical conditions - Elevated cholesterol can be caused by conditions such as liver disease,
diabetes, kidney disease or thyroid disease.
Age and gender - Men and women at around the age of 20 starts to raise their cholesterol
level. Compared with men of the same age, pre-menopausal women usually have lower levels
of  cholesterol.  After menopause,  women risks  for  heart  disease increase since their  LDL
cholesterol levels typically go up.
Physical activity - Lack of exercise can cause a raise in the LDL levels and a lowering in the 
HDL levels. Increased physical activity will cause the opposite.
Alcohol use: Moderate alcohol intake increases HDL cholesterol but does not lower LDL
cholesterol. Doctors don't know for certain whether alcohol also reduces the risk of heart
disease. Drinking too much alcohol can damage the liver and heart muscle,  lead to  high
blood pressure, and raise triglyceride levels. Because of the risks, alcoholic beverages should
not be used as a way to prevent heart disease. 
Mental stress Stress raises blood cholesterol levels over the long term. One way that stress
may do this is by affecting your habits. For example, when some people are under stress,
they console themselves by eating fatty foods.  The saturated fat  and cholesterol in these
foods contribute to higher levels of blood cholesterol.
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Signs and symptoms:
Symptoms that may occur include:
• Fatty, cholesterol-rich skin deposits (xanthomas) 
• Cholesterol deposits in the eyelids (xanthelasmas) 
• Chest pain (angina) associated with coronary artery disease 
• Obesity 
Persons with either one or two copies of the defective gene can develop fatty skin deposits
over their elbows, knees, buttocks, tendons, and around the cornea of the eye.
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1.5 Dysphagia and Fast Disintegrating Tablets (FDTs)
Dysphagia, or difficulty in swallowing, is common among all age groups. According to a
study by Sastry et al., dysphagia is common in about 35% of the general population, as well
as an additional 30–40% of elderly institutionalized patients and 18–22% of all persons in
long-term care facilities. Common complaints about the difficulty in swallowing tablets in the
order of frequency of complaints are size, surface, form, and taste of tablets. Geriatric and
pediatric patients and traveling patients who may not have ready access to water are most in
need of easy swallowing dosage forms. Another study shows that an estimated 50% of the
population suffers from this problem. These studies show an urgent need for a new dosage
form that  can  improve  patient  compliance.  Solid  dosage  forms  that  can  be  dissolved  or
suspended with water in the mouth for easy swallowing are highly desirable for the pediatric
and geriatric  population, as well  as other  patients who prefer  the convenience  of readily
administered dosage forms.  Although chewable tablets have been on the market  for some
time, they are not the same as the new oral disintegrating tablets (ODTs). 
Patients for whom chewing is difficult or painful can use these new tablets easily. ODTs can
be used easily in children who have lost their primary teeth but do not have full use of their
permanent teeth. Recent market studies indicate that more than half of the patient population
prefers ODTs to other dosage forms and most consumers would ask their doctors for ODTs
(70%), purchase ODTs (70%), or prefer ODTs to regular tablets or liquids (>80%).  During
the last decade, fast disintegrating tablet (FDT) technologies that make tablets disintegrate
in  the  mouth  without  chewing  and  additional  water  intake  have  drawn  a  great  deal  of
attention. 
                                                The FDT is also known as fast melting, fast dispersing, rapid
dissolve, rapid melt, and/or quick disintegrating tablet. All FDTs approved by the Food and
Drug  Administration  (FDA)  are  classified  as  orally  disintegrating  tablets.  Recently,  the
European Pharmacopeia adopted the term orodispersible tablet  for a tablet that disperses or
disintegrates  in  less  than  3  minutes  in  the  mouth  before  swallowing.  Such  a  tablet
disintegrates  into smaller  granules  or  melts in  the mouth from a hard solid to  a gel-like
structure, allowing easy swallowing by patients. The disintegration time for good FDTs varies
from several seconds to about a minute.
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1.5.1 Advantages of FDTs
FDTs have all the advantages of solid dosage forms, such as good stability, accurate dosing,
easy manufacturing, small packaging size, and easy handling by patients. FDTs also have the
advantages of liquid formulations,  such as easy administration and no risk of suffocation
resulting from physical obstruction by a dosage form.
                           The primary patients for FDTs are pediatric, geriatric, and bedridden or
developmentally disabled patients;  patients with persistent  nausea;  and patients who have
little or no access to water. Application of FDTs can of course be extended to more general
patients of daily medication regimens.  From the pharmaceutical  industry’s  point  of  view,
FDTs can provide new dosage forms as a life cycle management tool for drugs near the end
of their patent life.
Because  the tablets  disintegrate  inside the  mouth,  drugs  may be  absorbed  in  the buccal,
pharyngeal,  and  gastric  regions.  Thus,  rapid  drug  therapy  intervention  and  increased
bioavailability of drugs are possible. Because the pre-gastric drug absorption avoids the first-
pass metabolism, the drug dose can be reduced if a significant amount of the drug is lost
through the hepatic metabolism.
1.5.2. DESIRED CHARACTERISTICS AND DEVELOPMENT CHALLENGES OF 
FAST DISSOLVING TABLETS (FDT):
Because administration of FDTs is different from administration of conventional tablets, the
FDTs should maintain several unique properties, as listed below.
A. Fast Disintegration
FDTs should disintegrate in the mouth without additional water or with a very small amount
(e.g., 1–2 ml) of water. The disintegration fluid is provided by the saliva of the patient. The
disintegrated tablet should become a soft paste or liquid suspension, which can provide good
mouth feel and smooth swallowing. The “fast disintegration” usually means disintegration of
tablets in less than 1 minute, but it is preferred to have disintegration as soon as possible.
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B. Taste of Active Ingredients
Because  FDTs  dissolve  or  disintegrate  in  the  patient’s  mouth,  the  drug  will  be  partially
dissolved in close proximity to the taste buds. After swallowing, there should be minimal or
no  residue  in  the  mouth.  A pleasant  taste  inside  the  mouth  becomes  critical  for  patient
acceptance. Unless the drug is tasteless or does not have an undesirable taste, taste-masking
techniques should be used. 
An ideal taste-masking technology should provide drugs without grittiness and with good
mouth feel. The amount of taste-masking materials used in the dosage forms should be kept
low “AS LOW AS POSSIBLE” to avoid excessive increase in tablet size. The taste-masking
technology should also be compatible with FDT formulations. For example, if drug particles
are coated to minimize unpleasant taste, the coating should not be broken during compression
or dissolved during wet granulation. Taste masking of bitter tasting drugs is critical to the
success of the FDT formulations.
C. Drug Properties
For the ideal FDT technology, the drug properties should not significantly affect the tablet
property.  Many  drug  properties  could  potentially  affect  the  performance  of  FDTs.  For
example, the solubility, crystal morphology, particle size, hygroscopicity, compressibility, and
bulk density of a drug can significantly affect the final tablet’s characteristics, such as tablet
strength and disintegration. The FDT technology should be versatile enough to accommodate
unique properties of each drug.
 Several  factors must be considered when selecting drug candidates for delivery as  ODT
dosage forms.  In  general,  an  ODT is  formulated as  a  bioequivalent  line  extension of  an
existing oral dosage form. Under this circumstance, it is assumed that the absorption of a
drug  molecule  from  the  ODT  occurs  in  the  postgastric  GIT  segments,  similar  to  the
conventional oral dosage form. But this scenario may not always be the case. An ODT may
have varying degrees of pre gastric absorption and thus, the pharmacokinetic profiles will
vary. Therefore, the ODT will not be bioequivalent to the conventional oral dosage form. For
example,  ODT formulations of  selegiline,  apomorphine,  and  buspirone have  significantly
different  pharmacokinetic  profiles  compared  with  the  same  dose  administered  in  a
conventional dosage form. It is possible that these differences may, in part, be attributed to
the drug molecule,  formulation,  or  a  combination of  both.  If  significantly higher  plasma
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levels  have  been  observed,  pregastric  absorption  leading  to  the  avoidance  of  first-pass
metabolism may play an important role. This situation may have implications for drug safety
and efficacy, which may need to be addressed and assessed in a marketing application for an
ODT.
 For example, safety profiles may be improved for drugs that produce a significant amount of
toxic metabolites mediated by first pass liver metabolism and gastric  metabolism and for
drugs that have a substantial fraction of absorption in the oral cavity and segments of the
pregastric GIT. Drugs having ability to diffuse and partition into the epithelium of the upper
GIT (log P >  1,  or  preferable  >  2);  and  those  able  to  permeate  oral  mucosal  tissue  are
considered  ideal  for  ODT  formulations.  Patients  who  concurrently  take  anticholinergic
medications may not be the best candidates for these drugs. Similarly, patients with Sjögren’s
syndrome or  dryness  of  the  mouth due to decreased saliva  production may not  be good
candidates for these tablet formulations. 
                                        Drugs with a short half-life and frequent dosing, drugs which are
very bitter or otherwise unacceptable taste because taste masking cannot be achieved or those
which require controlled or sustained release are unsuitable candidates of rapidly dissolving
oral dosage forms. Researchers have formulated ODT for various categories of drugs used for
therapy  in  which  rapid  peak  plasma  concentration  is  required  to  achieve  the  desired
pharmacological  response.  These  include  neuroleptics,  cardiovascular  agents,  analgesics,
antiallergic,  anti-epileptics,  anxiolytics,  sedatives,  hypnotics,  diuretics,  anti-parkinsonism
agents, anti-bacterial agents and drugs used for erectile dysfunction.
D. Tablet Strength and Porosity
Because FDTs are designed to have a quick dissolution/disintegration time, the tablet porosity
is usually maximized to ensure fast water absorption into the tablets. The key properties of
the  tablets  are  fast  absorption  or  wetting  of  water  into  the  tablets  and  disintegration  of
associated  particles  into  individual  components  for  fast  dissolution.  This  requires  that
excipients should have high wettability, and the tablet structure should also have a highly
porous network.  Because the strength of  a tablet  is  related to compression pressure,  and
porosity is inversely related to compression pressure, it is important to find the porosity that
allows fast water absorption while maintaining high mechanical strength. In addition, low
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compression pressure causes fast dissolving dosage forms to be soft, friable, and unsuitable
for packaging in conventional blisters or bottles.  A strategy to increase tablet  mechanical
strength without sacrificing tablet porosity or requiring a special packaging to handle fragile
tablets should be provided.
E. Moisture Sensitivity
FDTs should have low sensitivity to humidity. This problem can be especially challenging
because  many  highly  water-soluble  excipients  are  used  in  formulation  to  enhance  fast
dissolving  properties  as  well  as  to  create  good  mouth  feel.  Those  highly  water-soluble
excipients are susceptible to moisture; some will even deliquesce at high humidity. A good
package  design  or  other  strategy  should  be  created  to  protect  FDTs  from  various
environmental conditions.
F. Palatability
As most drugs are unpalatable, orally disintegrating drug delivery systems usually contain the
medicament in a taste-masked form. Delivery systems disintegrate or dissolve in patient’s
oral cavity, thus releasing the active ingredients which come in contact with the taste buds;
hence, taste-masking of the drugs becomes critical to patient compliance.
G. Amount of drug
The application of technologies used for ODTs is limited by the amount of drug that can be
incorporated into each unit dose. For lyophilized dosage forms, the drug dose must be lower
than 400 mg for insoluble drugs and less than 60 mg for soluble drugs. This parameter is
particularly challenging when formulating a fast-dissolving oral films or wafers
H. Aqueous solubility
Water-soluble  drugs  pose  various  formulation  challenges  because  they  form  eutectic
mixtures, which result in freezing-point depression and the formation of a glassy solid that
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may collapse upon drying because of  loss of supporting structure during the sublimation
process.  Such  collapse  sometimes  can  be  prevented  by  using  various  matrix-forming
excipients such as mannitol than can induce crystallinity and hence, impart rigidity to the
amorphous composite.
I. Size of tablet
The degree of ease when taking a tablet depends on its size. It  has been reported that the
easiest size of tablet to swallow is 7-8 mm while the easiest size to handle was one larger than
8 mm. Therefore, the tablet size that is both easy to take and easy to handle is difficult to
achieve.
Various patents involved in ODT are mentioned in Table no 5
Advantages and disadvantages of ODT’s are mentioned in table no 6
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1.5.3 Approaches to ODT Development
The fast disintegrating property of the tablet is attributable to a quick ingress of water into the
tablet  matrix  resulting in its  rapid disintegration. Hence,  the basic approaches to develop
rapidly dissolving oral dosage forms include maximizing the porous structure of the tablet
matrix,  incorporating  the appropriate  disintegrating agent  and using highly water  soluble
excipients in the formulation.  As is often the case, a technology that is originally developed
to  address  a  particular  administration  need  can  quickly  become  adopted  as  part  of  a
pharmaceutical company’s product life cycle management strategy, which is precisely what
has  happened  with  ODT technologies.  Several  patented  technologies  with  their  basis  of
formulation are listed in Table 5. The technologies that have been used by various researchers
to prepare orally disintegrating dosage forms include: 
1. Freeze- Drying or Lyophilization, 
2. Molding,
3. Direct Compression,
4. Disintegrant addition,
5. Sublimation, 
6. Spray Drying, 
7. Mass Extrusion, 
8. Cotton-candy process, 
9. NanoCrystalTM Technology,
10. Oral films/wafers. 
Marketed products of the various ODT technologies are listed in table 7
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TABLE NO.5: ODT PATENTS
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TABLE NO. 6 ADVANTAGES AND DISADVANTAGES OF ODT TECHNOLOGIES
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TABLE NO. 7: SOME OF THE MARKETED ODT FORMULATIONS
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1.6 WOWTAB® Technology
WOWTAB technology employs a combination of low- and high-moldability saccharides to
produce  fast-dissolving  tablets  using  conventional  granulation  and  tableting  techniques.
According to the patent, saccharides were divided into two groups:
 Those with high moldability and 
 Those with low moldability. 
                                                   Low moldability saccharides produce tablets with hardness
between 0 and 2 kg, when 150 mg of such a saccharide is compressed under pressure of 10–
50 kg/cm using a die 8 mm in diameter. 
The  typical  low-moldability  saccharides  include  lactose,  mannitol,  glucose,  sucrose,  and
xylitol. 
                                                 High-moldability saccharides produce tablets with hardness
above 2  kg  when prepared  under  the  identical  conditions.  The  typical  high-  moldability
saccharides are maltose, maltitol, sorbitol, and oligosaccharides.
When  tablets  are  made  by  compressing  a  saccharide  having  low  moldability  or  high
moldability alone, the desired properties of adequate hardness and quick disintegration in the
mouth cannot be achieved simultaneously. Moreover, if saccharides having low moldability
and high moldability are mixed (physical mixture) before tableting, quick disintegration and
dissolution in the mouth cannot be obtained. As clearly indicated in the patents, there is no
single saccharide that  can make tablets  having both high strength  and  fast  disintegration
properties.  For  this  reason,  a  saccharide  having  low  moldability  was  granulated  with  a
saccharide having high moldability as a binder. The low-moldability saccharides were used as
the main component. Tablets made by compression of these granules were further treated
under moisture condition as described in Figure 5. The tablets show an adequate hardness and
fast disintegration and dissolution when put in the mouth.
Intrabuccally dissolving compressed moldings comprising of saccharide with low moldability
having been granulated with saccharide having high moldability. These moldings show quick
disintegration and dissolution in the buccal cavity and have an adequate hardness and suitable
for both bottle packing and blister packing.
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The term “intra buccally dissolving compressed moldings” means they have a practically
sufficient disintegration and dissolution by saliva by merely keeping in the mouth with out
holding water in the buccal cavity and which have adequate hardness.
The term “practically sufficient disintegration and dissolution
means  that  the  moldings  disintegrate  or  dissolve  in  the  buccal  cavity in  appx.  1  to  120
seconds preferably with in 1 to 60 seconds and more preferably with in 1 to 40 seconds. 
Mizumoto et al.,  [2,  3] have classified sugar-based excipients into two types based on their
mouldability and dissolution rate.
Type I saccharides (e.g., lactose and mannitol) exhibit low moldability but high dissolution
rate.
Type II saccharides (e.g., maltose and maltitol) exhibit high moldability but low dissolution
rate. .( Shukla et al.: Sci Pharm. 2009; 76; 309–326).
Moldability is defined as the capacity of the compound to be compressed/ molded and to
dissolve.  It  does not refer to the formation of  a true mold by melting or solvent wetting
process. 
The moldability  of  Type I  saccharide  can  be improved  by granulating it  with  a  Type II
saccharide solution. The above technology forms the basis of WOWTAB [5] which involves
the use of fluidized bed granulation for the surface treatment of Type I saccharide with Type
II saccharide.                      
 This technique has been used in the production of Benadryl Fast melt tablets. Here, two
different  types  of  saccharides  are combined to obtain a  tablet  formulation with adequate
hardness  and  fast  dissolution  rate  [7].  Due  to  its  significant  hardness,  the  WOWTAB
formulation is more stable to the environmental conditions than the Zydis or Orasolv and is
suitable for both conventional bottle and blister packaging. 
                                                The taste masking technology utilized in the WOWTAB is
proprietary and claims to offer superior mouth feel due to the patented smooth-melt action
[5]. In the process of granulation, low moldable sugar was coated with high moldable sugar
followed by a specific humidity treatment, to achieve fast disintegration. The resulting tablet
had a hardness of 1.0–2.0 kg (tablet-size dependent) and presented a preferable disintegration
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time  of  1–40  secs.  Various  classes  of  drugs  can  be  incorporated  into  the  above  sugar
combination to achieve a MDT with optimum performance characteristics. 
                                             A preferable ratio of 5–10% w/w of high moldable sugar was
found to be sufficient to achieve the desired hardness and disintegration property A series of
experiments had been conducted to develop a MDT using a combination of starch/cellulose
and one or more water-soluble saccharides [32]. Erythritol was found to be the best saccharide
because  it  displayed  rapid  disintegration,  good  tolerability,  sweetening  and  a  refreshing
mouth feel due to its negative heat of solution.
Recently, the Ziplet technology was developed, which can be used for water insoluble drugs
or drugs as coated micro particles. It was found that the addition of a suitable amount of a
water-insoluble  inorganic  excipient  combined  with  one  or  more  effective  disintegrants
imparted an excellent physical resistance to the MDT and simultaneously maintained optimal
disintegration even at low compression force and tablet hardness [26]. In fact, breakage of the
tablet edges or formation of powder during manufacturing and opening of the blister pack is
avoided because of its superior mechanical resistance. The use of water-insoluble inorganic
excipients also offers better enhancement of disintegration characteristics in comparison to
the most commonly used water-soluble sugars or salts. In fact, tablets composed primarily of
water-soluble components often tend to dissolve rather than disintegrate, resulting in much
longer disintegration time. As the soluble components dissolve on the tablet’s outer layer, a
concentrated viscous solution is formed, which reduces the rate of water diffusion into the
tablet core
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1.7 TYPES OF GRANULATION BY WOW TEHNOLOGY:
1. An active ingredient added to a low moldability saccharide and the resulting mixture
is granulated with a high moldability saccharide
2. A low  moldable  saccharide  is  granulated  with  a  high  moldable  saccharide.  The
resulting granules are mixed with an active ingredient, and the resulting mixture is
subjected to compression.
3. A low moldability saccharide is granulated with high moldabilty saccharide to obtain
granules. Separately active ingredient is granulated with high moldability saccharide
to obtain granules. These granules are mixed and subjected to compression.
4. A low moldability saccharide is granulated with both of an active ingredient and a
high moldability saccharide in any order. The resulting are granules are subjected to
compression.
5. A low  moldability  saccharide  (central  core)  is  coated  with  a  high  moldability
saccharide (first layer) and then coated with an active ingredient (second layer), and
the resulting product is granulated with a high moldable saccharide (third layer). The
resulting granules are subjected to compression.
6. A low moldability  saccharide  is  coated  with  an  active  ingredient  and  the  coated
product is granulated with a high moldability saccharide. The resulting granules are
compressed.
The active ingredient may be used in an amount of 50% (w/w) or less preferably
20%w/w or less because of total solid components.
The blending ratio of high moldable saccharide to low moldable saccharide of from 2
to 20% by weight preferably from 5 to 10% by weight.
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1.7 ADDITIVES USED IN WOW TECHNOLOGY:
Various additives can be added to the formulation as long as they do not spoil the effects of
present invention. They include
1. Disintegrating agents
2. Binding agents
3. Souring agents
4. Vesicants
5. Artificial sweeteners
6. Perfumes
7. Lubricants
8. Coloring agents
1.7.1 DISINTEGRANTS USED IN FAST DISSOLVING TABLETS:
Some patents use effervescent couples as their disintegrant, while others use a combination of
disintegrants. Dobetti summarized different types of non-effervescent disintegrants used in
the pharmaceutical area.
• Starch and modified starches. This group includes natural starches (such as maize
Starch and potato starch), directly compressible starches (such as starch 1500),
Modified starches (such as carboxymethylstarches and sodium starch glycolate),
and starch derivatives (such as amylose).
• Cross-linked polyvinyl pyrrolidone
• Modified celluloses such as cross-linked sodium carboxymethylcellulose
• Alginic acid and sodium alginate
• Microcrystalline cellulose
• Methacrylic acid-divinylbenzene copolymer salts
In addition, poly (acrylic acid) super porous hydrogel (SPH) micro particles were recently
reported  as  super  disintegrants  possessing a  unique  porous  structure.  They were  used  as
wicking agents to decrease the disintegration time of FDTs. The poly (acrylic acid) SPH
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micro particles can swell approximately 80 times in distilled water and 50 times in pH 6.8 0.2
M phosphate buffer. The SPH micro particle size had a significant effect on the disintegration
time and tensile strength of ketoprofen FDTs. The minimum disintegration time was observed
when the microparticle size was in the range of 75–106 µm. Tensile strength of the tablets
decreased  as  the  SPH  micro  particle  sizes  decreased  from  180–250  µm  to  25–44  µm.
However, when the micro particle sizes were smaller than 25 µm, the tensile strength of the
resultant tablets increased as the size decreased. The optimal micro particle size should be in
the range of 75–106 µm. The FDTs made of SPH micro particles in the range of 75-106 µm
showed the fastest disintegration time (15 ± 2.0 s) and higher tensile strength (84.4 +/- 4.1
N/cm).
1.7.2 Binding agents:
Powdered acacia, gelatin, pullulan etc
1.7.3 Souring agents:
Citric acid, tartaric acid, malic acid
1.7.4 Vesicants
Sodium bicarbonate
1.7.5 Artificial sweeteners
Saccharin sodium, glycyrrhizin, aspartame, stevia, thaumatin.
1.7.6 Perfumes
Lemon, lemon lime, orange, menthol
1.7.7 Lubricants
Magnesium state, sucrose fatty acid esters, polyethylene glycol, talc, stearic acid
1.7.8 Coloring agents
Food dyes, Food Lake dyes, red iron oxide
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1.8 COMPACTION AND SUBSEQUENT TREATMENTS
a. Sublimation
The slow dissolution of the compressed tablet containing even highly water-soluble
ingredients is due to the fact that the low porosity of the tablets reduces water penetration
into the matrix. When volatile materials are compressed into tablets using the conventional
method,  they can be removed via sublimation,  resulting in  highly porous structures.  The
volatile  materials  include  urea,  ammonium  carbonate,  ammonium  bicarbonate,  hexa
methylene tetramine, and camphor. Heinemann disclosed a process to prepare porous tablets
by  sublimation.  The  mixtures  of  volatile  adjuvants  were  made  into  tablets,  which  were
subsequently heated to remove them. Roser and Blair used vacuum to remove the volatile
materials. The full dissolution time was reduced from 10–15 minutes for the tablets formed
from trehalose alone to less than 1 minute. In some cases, menthol, camphor, thymol, an
organic acid such as adipic acid, and a lower fatty acid such as arachidic acid, capric acid,
myristic  acid,  and  palmitic  acid were used as  the volatile  materials,  and the  sublimation
temperature ranged from 40 to 60C. The disintegration time in the human mouth was claimed
to be about 25 seconds. Lo disclosed an efficient method for preparing high-strength, highly
porous, fast-dissolving delivery devices. In this method menthol, a water-soluble, menthol
soluble polymer, and an active ingredient are mixed at a temperature that insures that the
menthol is substantially molten. The formulation is disposed in a mold and solidified, and the
menthol is sublimed from the solidified molded formulation. Preferably,  the solidification
occurs at a temperature sufficient to provide a substantially amorphous menthol structure.
b. Humidity Treatment
The mechanical strength of some tablets increased substantially after moisture treatment,
compared  with  the tablets  before the  treatment.  The increase  is  known to be due  to  the
formation of liquid bridges in the presence of moisture and then formation of solid bridges
after drying. As shown in Fıgure 5, when solid particles start to pick up moisture from the
atmosphere, the water is adsorbed onto the surface (A), and then water molecules form a film
on it with the vapor pressure over the adsorbed moisture layer equal to Pb (B). The solid
starts to dissolve into the adsorbed moisture layer, and the dissolution of solid in the adsorbed
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moisture  will  lead  to  a  decrease  in  the  vapor  pressure  Pb  (C).  The  decrease  in  Pb  is
effectively off set by the increase in temperature of the film (and the solid) caused by the heat
released on condensation of the water vapor. The moisture sorption occurs spontaneously, and
the thickness of the condensate film grows as long as Pa > Pb. The solid continues to dissolve
and saturate the film, maintaining the vapor pressure over the adsorbed moisture layer (Pb).
After drying, a solid bridge is believed to occur and increase bonding between the particles
(D).
It is also known that certain types of sugar change from the amorphous to the crystalline state
when their solution is spray dried or used as a binder solution. Further investigations have
shown that when an amorphous sugar is treated to go through the humidification and drying
process,  it  changes  to  a  crystalline  state.  This  change  increases  the  tablet  strength
substantially.  The  conceptual  process  of  structural  changes  of  amorphous  sucrose  to
crystalline sucrose is shown in Fıgure 6.
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In a patent by Mizumoto et al.,(2,  3,  4) a drug, a sugar, and an amorphous sugar capable of
transforming from amorphous to crystalline state were mixed and compressed into tablets.
After the tablets were formed, they were humidified and dried. The amount of the sugar in the
formulation can be adjusted according to the drug content and tablet size. The “amorphous
sugars” are those that can form an amorphous state by spray drying, freeze drying, or other
granulation methods.  These amorphous sugars  include glucose,  lactose,  maltose,  sorbitol,
trehalose, lactitol, and fructose. The relative humidity is determined by the apparent critical
relative humidity of  the mixture  of  a  drug and an amorphous sugar.  A relative  humidity
greater  than  or  equal  to  the  critical  relative  humidity  of  this  mixture  is  chosen  for  the
humidity condition. The advantage of using amorphous sugars is that they have low critical
relative humidity, so that they can absorb water even at low moisture levels. The crystalline
form of the sugars has difficulty in controlling moisture absorption. Moisture absorption of
the crystalline form is not sufficient to strengthen the tablets at a low humidity condition. If a
high  humidity  condition  is  used,  tablets  may  adhere  together,  causing  manufacturing
problems.  Another  advantage  of  using  amorphous  sugars  is  that  transformation  of  the
amorphous state to the crystalline state is irreversible. The sugars in crystalline state have a
high critical moisture point, so the strengthened tablets are less susceptible to moisture.
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 Liu et al. disclosed a system for making FDTs by humidity treatment. 
The process includes the following steps: 
(1) a water-soluble polymer was used as a binder solution to granulate active ingredients and
other excipients, such as low moldability sugars;
(2) the granules were then compressed into tablets; 
(3) the tablets were humidified at relative humidity of about 50–100%; and 
(4) the tablets were dried. 
The hardness of the tablet was about 0.5–12.0 kilo pounds, and the in vivo disintegration time
was claimed to be about 1–40 seconds.
Tatara et  al.  also used moisture treatment and devised an apparatus  to handle the fragile
tablets before moisture treatment. An active ingredient and other excipients were compressed
in  low pressure,  and  then  the  resultant  tablets  were  moisturized  and  dried  to  produce  a
porosity between 20 and 40%. As shown in Fıgure 7, the manufacturing apparatus includes a
rotary punch-press, a relay conveyor for transferring tablets, a moisturizing section, a drying
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section, and a delivery conveyor. In the moisturizing section, the condition was set to allow
tablets
Moisturized at 45 oC, 95% relative humidity for 60 seconds. In the drying section, the
temperature was set to 50  oC for 60 seconds. With this apparatus the fragile tablets before
moisture treatment were gently transferred throughout the process.
c. Sintering
Lagoviyer  et  al. disclosed  a  process  that  increased  tablet  strength  by sintering  the tablet
components at high temperatures and then re solidifying them at lower temperatures. The
components in this formulation include bulk agents, structure agents, solvent, and binding
agents. A bulk agent in this formulation is used to provide bulk volume to the overall tablet,
and suitable agents include carbohydrates, calcium carbonate, and magnesium carbonate. The
suitable structure agents should provide a porous support structure to allow quick dissolution
of  the  tablets  in  the  mouth.  The  structural  agents  include  agar,  gelatin,  albumin,  and
chondroitin.  Bulking  and  structural  agents  were  dissolved  in  a  suitable  solvent,  and  the
dissolved mixture was spray dried or dispersed to obtain a bead or granulated product with a
low density. Choice of the solvent is based on its ability to provide a desired porosity to the
bead or granulated product upon drying. Solvents can be chosen from water, ethyl alcohol,
isopropyl alcohol, or a mixture thereof. The binders need to melt at the sintering stage, form
bonding among granules, and re solidify as the temperature of the final sintering or heating
step decreases. Binders are water soluble polymers such as poly(ethylene glycol) (PEG), with
a molecular weight of approximately 1000 to 1,000,000. PEG melts at 50–90 oC, PEG has the
advantage of functioning both as a binder and as a capillary attractant. The amount of binding
polymer ranged from 0.5% to 25% of the weight of the final product. The binding agents and
active ingredients can be introduced to the formulation in several ways. A binding agent and
active ingredient can also be dry blended to the spray-dried or dispersed granulated product.
They can alternatively be dissolved into solvent with bulking agent  and spray dried into
granules. The granules are then lightly compressed to form tablets. These tablets are heated
for a sufficient time and temperature to allow the binding agent to melt. The heating step is
intended to melt the binding agent to create intra-tablet bonds and help weld the product
shape together. Typically,  a laboratory oven is set at around 50–100 oC, The heating time
ranges from 3  to  45 minutes.  The binding agents  are  re  solidified as  the temperature  is
reduced to ambient temperature. The disintegration time is generally within 3–60 seconds.
42
                                                                                                      Introduction
The  heat  treatment  or  sintering  step  in  the  patent  improved  the  product’s  strength  and
durability. Because the active ingredient can be introduced into the formulation in several
ways,  taste-masking technologies can be easily incorporated into the process.  The dosage
form  allows  the  incorporation  of  a  wide  range  of  dosage  levels.  Because  of  the  high
temperature treatment, when heat-labile drugs are incorporated in the formulation, careful
attention  should  be  given  in  this  process.  The  advantages  and  disadvantages  of  the
technologies describe here are summarized in  Table 6. These technologies  are commonly
applied to the production and development of FDTs.
Advantages of WOWTAB technology:
 Smooth melt action in the mouth because of use of saccharides
 Sufficient hardness suitable for both blister packing and bottle packing
 Special taste masking technology is not necessary unless the drug is highly bitter
 Enhanced patient compliance because of ease of administration
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1.9 ODT Evaluation of Special Concern
Crushing strength and friability can be assessed as stated in pharmacopoeias. But some tests
are of special concern and these include the following:
Wetting time
Wetting time of dosage form is related to the contact angle. It needs to be assessed to give
an insight into the disintegration properties of the tablets; a lower wetting time implies a
quicker disintegration of the tablet. For this purpose, a tablet is placed on a piece of tissue
paper folded twice and kept in a small Petri dish (ID = 6.5 cm) containing 6 ml of water,
and the time for complete wetting is measured.
Disintegration test
The  time  for  disintegration  of  ODTs  is  generally  less  than  one  minute  and  actual
disintegration  time  that  patient  can  experience  ranges  from  5-30  seconds.  The  standard
procedure of performing disintegration test for these dosage forms has several limitations and
they are not suitable for the measurement of very short disintegration times.  The method
needs to  be modified for  ODTs as  disintegration is  required without  water;  thus  the test
should mimic disintegration in salivary contents. A modified dissolution apparatus is applied
to an ODT with a disintegration time that is too fast to distinguish differences between tablets
when the compendial method is used. A basket sinker containing the tablets is placed just
below the water surface in a container with 900 mL of water at 37 0C, and a paddle rotating at
100  rpm  is  used.  The  disintegration  time  is  determined  when  the  tablet  has  completely
disintegrated and passed through the screen of the sinker.  Various scientists have developed
new  in vitro  methods  that  allow  an  accurate determination  of  disintegration  test.  The
disintegration test is performed using a texture analyzer instrument. In this test, a flat-ended
cylindrical probe penetrates into the disintegrating tablet immersed in water. As the tablet
disintegrates, the instrument is set to maintain a small force for a determined period of time.
The plots of some distance traveled by the probe generated with the instrument’s software
provide  disintegration  profile  of  the tablets  as  a  function  of  time.  The  plot  facilitates
calculation of the start and end-point of the tablet disintegration.
Dissolution test 
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The development of dissolution methods for ODTs is comparable to the approach taken for
Conventional tablets, and is practically identical. Dissolution conditions for drugs listed in a
pharmacopoeia monograph, is a good place to start with scouting runs for a bioequivalent
ODT. Other media such as 0.1 M HCl and buffer (pH 4.5 and 6.8) should be evaluated for
ODT much in the same way as their ordinary tablet counterparts. It has been suggested that
USP 2 paddle apparatus is the most suitable and common choice for orally disintegrating
tablets, with a paddle speed of 50 rpm commonly used.
Moisture uptake studies 
Moisture uptake studies for ODT should be conducted to have an insight into the stability of
the  formulation,  as  several  excipients  used  are  hygroscopic.  Ten  tablets  from  each
formulation are kept in a desiccator over calcium chloride at 370C for 24 h. The tablets are
then weighed and exposed to 75% RH at room temperature for two weeks.  The required
humidity (75% RH) is achieved by keeping saturated sodium chloride solution at the bottom
of the desiccator for three days. One tablet as control (without superdisintegrant) is kept to
assess the moisture uptake due to other excipients. Tablets are weighed and the percentage
increase in weight is recorded
1.10 Packaging of ODT
Packing is one of the important aspects in manufacturing ODT. The products obtained by 
various technologies vary in some of the parameters especially in mechanical strength to a 
good extent. The products obtained by lyophilization process including various technologies 
such has Zydis, Lyoc, Quicksolv, and Nanocrystal are porous in nature, have less physical 
resistance, sensitive to moisture, and may degrade at higher humidity conditions. For these 
reasons products obtained require special packing. Zydis units are generally packed with 
peelable backing foil. Paksolv is a special packaging unit, which has a dome-shaped blister, 
which prevents vertical movement of tablet with in the depression and protect tablets from 
breaking during storage and transport, which is used for Orasolv tablet. Some of the products 
obtained from Durasolv. WOW Tab, Pharmaburst oraquick, Ziplets, etc. technologies have 
sufficient mechanical strength to withstand transport and handling shock so they are generally
packed in push through blisters or in bottles.
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1.11 Patient counseling in effective use of ODT
ODT developed offers significant advantages for various group of patients, but the majority 
of patients receiving ODT have little understanding of this novel dosage form. Patients 
receiving ODT may be surprised when tablets begin to disintegrate/dissolve in mouth. As 
pharmacists are ideal persons to know about the recent technologies, thus have opportunity to
educate the patients for effective treatment.
Counseling of patients about this dosage form can avoid any confusion and misunderstanding
in taking ODT. Patient information that needs to be provided includes:
• Storage  of  this  dosage  form as  some of  ODT developed  may not  have  sufficient
mechanical strength, which needs to be handled carefully. 
• Patients with Siogren's syndrome or dryness of mouth or who take anti cholinergic
drugs may not be suitable candidates for administering ODT. Although no water is
required to allow drug to disperse quickly and efficiently but decreased volume of
saliva  may  slow  the  rate  of  disintegration/dissolution  and  may  reduce  the
bioavailability of the product. 
• Patients need to be clearly told about the difference between effervescent and ODT.
Some of technologies use effervescence, which experience a pleasing tingling effect
on the tongue. 
• Although chewable tablets are available in market and patient need to be counseled
about differences between chewable and ODT tablets. This ODT can be used easily in
children who have lost their primary teeth and in geriatric patients who have lost their
teeth permanently.
With  the  pharmacists  counseling,  intervention  and  assistance  about  ODT,  all  patients
receiving this novel dosage form could be more properly and effectively treated with greater
convenience
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II. RESEARCH ENVISAGED
2.1 Need for Study
The research can be seen as work that tries to find new products and processes or to improve
existing one. The ultimate object of any research done in the field of pharmaceuticals is to
serve the society’s need by developing a formulation that is highly efficient. For this research
to be successful, the work to be done should be logically and properly planned based on the
literature surveyed.
The  term  solid  dispersion  refers  to  a  group  of  solid  products  consisting  of  atleast  two
different components, generally a hydrophilic matrix and a hydrophobic drug. The matrix can
be either crystalline or amorphous. The drug can be dispersed molecularly,  in amorphous
particles or in crystalline particles. Confusingly, in various studies the designation of solid
dispersion  is  based  on  the  method  of  preparation.  However,  since  different  preparation
methods can result in the same subtypes or similar preparation methods can result in different
subtypes, it can be argued that solid dispersions should preferably be designated according to
their  molecular  arrangement.  Moreover,  not  the  preparation  method  but  the  molecular
arrangement governs the properties of solid dispersion. Therefore, it is essential to use terms
that  indicate  the  molecular  arrangement  in  the  solid  dispersion.  Knowledge  about  the
molecular arrangement will enlarge comprehension of the properties and behavior of solid
dispersions.  The  mechanism  underpinning  dissolution  of  solid  dispersions  is  poorly
understood.  A question  like,  “is  the  drug  present  as  crystalline  phase  or  as  amorphous
molecularly dispersed throughout the matrix” is rarely discussed.  
Finally, the influence of drug load and method of preparation on dissolution behaviour and
stability of solid dispersions can only be understood and predicted when the relation between
these characteristics and the mode of incorporation is known.
The focus of the current  study is firstly to enhance the solubility of Fenofibrate by solid
dispersion  technique  and  to  study solid  state,  drug  carrier  interactions  and  to  prevent  re
crystallization of drug from solid dispersions. Secondary objective is to formulate an oral
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disintegrating tablet to enhance the drug release and to provide a smooth melt action in the
mouth and finally evaluate the tablets dissolution profile.  
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III. LITERATURE REVIEW
3.1 Literature Review of Fenofibrate
The primary drug information about Fenofibrate was researched from various well known
sources like Physicians' Desk Reference (PDR), Rx list, American Society of Health System
Pharmacists,  American Hospital  Formulary Service.  An attempt was made to compile the
research works reported in the versions scientific journals and advent text books on Solid
dispersion technology. 
Fenofibrate belongs to antihyperlipidemic class. It causes the decrease in the levels of low
density  lipoproteins(LDL),  and  very  low  density  lipoproteins(VLDL),  and  increases  the
levels of high density lipoproteins(HDL). 
 Luis Brito et al.,(2006); has studied the effect of powder processing on performance
of Fenofobrate oral disintegrating tablets to find the effect of blending and jet milling
of the drug alone and with the excipients on the disintegration time and the release
profile of the fenofibrate
 P. Srinarong  et   al.,(2009);   were  studied  the  dissolution profile  of  naproxen  in
binary and ternary solid dispersions of PEG (4000,6000,20000) with or without non
ionic  and  anionic  surfactants  prepared  by  melting  method.  They  found  better
dissolution from ternary systems than from binary systems since in the former the
wetting and solubilizing effects of surfactant and polymer were additive.
 Shahla Jamzad et  al.,(2006);  has  studied  the  role  of  Surfactant  and  pH  on
Dissolution Properties of Fenofibrate. It was concluded that Fenofibrate is a lipophilic
compound and practically insoluble in water. Hence, dissolution study of fenofibrate
dosage forms necessitates modifications in the dissolution medium to increase the
solubility.  Having no ionizable group, fenofibrate solubility was not influenced by
changes in medium pH. However, the addition of surfactants is a reasonable approach,
which if implemented correctly can approximate the GI fluid condition.
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 Ming-Thau Sheu  et  al.,(2002); has  done  the  Characterization  and  dissolution  of
fenofibrate  solid  dispersion  systems   with  PEG 6000  and  PVP.  The  effect  of  co
solvency and particle size on the dissolution profile has been studied and dissolution
rate was decreased with increase in PEG 6000 concentration and decrease in particle
size.
 D Law et al.,(2008);  has.  Investigated the physicochemical and biopharmaceutical
characteristics of fenofibrate in amorphous and eutectic solid dispersions with PEG
8000 and PVP K 17. The  in vivo performance of the two systems showed that the
eutectic PEG system achieved a greater AUC than the amorphous PVP system. It was
concluded  that  lipophilic  compound  can  form both  amorphous  and  eutectic  solid
dispersions with different polymers
 Payam Zahedi et al.,(2006);  characterize physicochemical parameters affecting the
formation of  solid molecular  dispersions  of  poorly water  soluble drugs in  poly(2-
hydroxyethyl  methacrylate)  hydrogels  and  to  investigate  the  effect  of  storage
humidity levels on their physical stability. Samples were prepared by an equilibrium
solvent loading process, the results show that a threshold drug loading level of about
30%, above which transition from amorphous to crystal was observed and also found
enhanced dissolution rate than pure drug.
 Ledjan Malaj et al.,(2010):  assessed the physical interaction between several aryl
propionic acid derivatives and polyvinyl(pyrrolidone)k30 stored together ar 298K at
different  releative humidities(RH 55,75,86%).  They found,  hydration of  drug-PVP
mixtures  had  important  repercussion  on  drug  solubility  and  intrinsic  dissolution
rate(IDR). In general, an increase in water solubility and consequently an increase in
IDR were observed, with few exceptions, at highest RH%. 
 Samer  al-dhalliet  al.,(2007); studied  the  potential  of  solid  dispersion-based
formulation using Gelucire 44/14 as  a  carrier  to  enhance the  dissolution and oral
bioavailability  of  fenofibrate,  PEG 400 was added  to  lower  the  melting  point  of
matrix  and  In  vivo  evaluation  of  fenofibrate-Gelucire  44/14  solid  dispersion
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containing polyethylene glycol (PEG) 400 showed that the extent of drug absorption,
expressed as AUC0-∞, was increased by approximately 60% over that of micronized
fenofibrate
 Tejas Patel et al., has studied the  enhancement of dissolution of Fenofibrate by Solid
dispersion  and  lyophilization  technique   using  PEG  6000,  Poloxamer  407  and  a
mixture of PEG 6000 and Poloxamer 407(1:1 mixture). The effect of melt and solvent
methods  of  preparation  of  solid  dispersion  on  dissolution  behavior  was  also
investigated. The dispersion containing six parts of the PEG 6000: Poloxamer 407
mixture (PEG 4000/PEG 6000, 1:1 mixture) showed a 12-fold increase in D60 as
compared with pure drug
 BASF   the  chemical  company has  characterized  the  graft  polymer  Soluplus  with
Fenofibrate  as  a  Fenofibrate  and  the solubility of  the  drug  has  been  significantly
enhanced in the 1:4 ratio of drug and polymer by hot melt extrusion method.
 Christian Leuner et  al.,(2000);  Review article  improving drug solubility for  oral
delivery using solid dispersions.
 Ruchi Tiwri et al.,(2009); Solid dispersion: An overview to modify bioavailability of
poorly water soluble drugs. International Journal of pharm Tech Research vol.1,no.4,
pp 1338-1349.
 Dhirendra  K et  al.,(2009);  Solid  dispersion:  A Review  Pak.J.Pharm.Sci,  Vol.22.
No.2,.april 2009, pp, 234-246.
 Patidar Kalpana et al.,(2010);Solid dispersion: Approaches, Technology involved,
Unmet need& challenges. Drug Invention Today Vol,2.Issue 7.July 2010.
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 V.Kamalakkannan et al., (2010); Solubility enhancement of poorly soluble drugs by
solid dispersion technique-A review. Journal of Pharmacy Research 2000,3(9),2314-
2321.
 Raja  rajeswari.  K  et  al.,  (2011); were  prepared  solid  dispersion  by  hot  melt
extrusion  of  Valsartan  with  soluplus.  They  found  1:9  ratio  of  drug  and  soluplus
showed 100% drug release from solid dispersion.
 Ravi  Kumar  et  al.,  (2009);  has  done  the  Formulation  Evaluation  of  Mouth
Dissolving  Tablets  of  Fenofibrate  Using  Sublimation  Technique  using  camphor,
thymol, ammonium bicarbonate and different concentrations of menthol using direct
compression  method.  menthol  at  12.5%  concentration  have  shown  quick
disintegrating features, i.e., within 20 s, which is very characteristic of orodispersible
tablets. The  in vitro  drug release study revealed that menthol at a concentration of
12.5 % (F10) of the dosage form weight was able to fast the release of Fenofibrate
within 10 minutes
 Yourong Fu et  al.,  (2004);  Critical  Reviews  in  Orally  Fast  Disintegrating  Tablet
Developments, Technologies, Taste-Masking and Clinical Studies.
 Jaysukh J Hirani et al., (2009); Orally Disintegrating Tablets: A Review
 Mizumoto T et al., (1996); Formulation design of a novel fastdisintegrating tablet.
Intrabuccally dissolving compressed moldings comprising a saccharide US 5576014
 Andries.  F.  Maris  et  al.,  (2003); were  studied  the  effect  of  compression  force,
humidity  and  disintegrant  concentration  on  disintegration  and  dissolution  of
furosemide tablets
 Late  SG  et  al.,  has  done  research  on  effect  of  disintegration  promoting  agent,
lubricants and moisture treatment on optimized fast disintegration tablets.
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 Chowhan ZT (1980) has studied the effect of low and high humidity ageing on the hardness,
disintegration time and dissolution rate of Dibasic calcium phosphate based tablets
 Suresh Bandari et al., Orodispersible tablets- An overview
53
                                                                                             Objective of study
IV. Objective of Study
• To enhance the solubility of Fenofibrate by solid dispersion technique.
• To optimize carrier and carrier concentration in the preparation of solid dispersions.
• To perform solubility of pure drug and solid dispersions.
• To characterize the solid state property of pure drug and solid dispersions by DSC, 
XRD, FTIR studies.
• To formulate the oral disintegrating tablets through wowtab technology.
• To optimize the moisture treatment of oral disintegrating tablets for attaining 
sufficient hardness and disintegration time.
• To evaluate the oral disintegrating tablets.
• To perform the stability study for optimized oral disintegrating tablets.
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VI. LIST OF EQUIPMENTS AND MATERIALS USED
Table 8: List of Equipments Used
S.No. Name of  the Equipment Model Supplier
1 Mechanical stirrer RZR 2102 control
      
2. Electronic weighing balance BBA422-3SM USA
3. Disintegration Test apparatus ED-2AL
4. Friabilator EF/W
5.
Laboratory oven DTC-00R
6. Compression machine CMD4
7. Stability chamber -
8. Tablet hardness tester Tablet tester 8M
9.
Induction cap sealear CsP 300
10.
UV-Shimadzu UV-2450
11. Quadraco mill 197 S
12.
Sieves -
13.
DSC 822 e
14.
XRD
15.
FTIR Spectrum
16. Dissolution apparatus TDT-08L
17.
Vernier calipers CD-6”CS
18. Tap density meter ETD-1020
19.
pH-Meter PH720
Table 9: Excipients employed and their suppliers
S.No. Excipients Supplier
1. API Matrix Laboratories Ltd.
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3. PVP K90
ISP Corporation  
4. Hydroxy propyl methyl
cellulose
            NISSO GROUP
5. Soluplus
BASF 
6. Microcrystalline cellulose
(Avicel 101)
7. Mannitol SD 200
8. Sorbitol
9. Polyplasdone xl
10. Kollicoat IR
11. Hydroxy propyl cellulose (ssl) NISSO GROUP
12. Magnesium stearate
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VII. DRUG PROFILE
The drug, belongs to fibrate class. It is used to reduce both low-density lipoprotien (LDL) and
very low density lipoprotein (VLDL) levels, as well as increasing  high-density lipoprotein
(HDL)  levels  and  reducing  triglycerides level  .  It  is  mainly  used  in  the  treatment  of
hypercholesterolemia. It  reduces cholesterol levels in patients at the risk of cardiovascular
diseases.
Structure:
Table 10: Physico – Chemical Properties of drug
Description White powder
Chemical name 2-[4-(4-chlorobenzoyl)  phenoxy]  2-methyl-propanoic acid, 1-methylethyl ester
Molecular formula C20H21O4Cl
Molecular weight 360.83
Solubility Insoluble in water; soluble in organic solvents like
ethanol, DMSO and DMF .
Melting point 80.5oC
Functional category
In  the  treatment  of hypercholesterolemia i.e.
presence  of  high  levels  of  cholesterol  due  to
abnormalities  in  the  levels  of  lipoproteins  like
LDL,VLDL,HDL.
Storage conditions Store cool, dry place.
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7.1 Site and Mode of Action:
The drug exerts its therapeutic effects through activation of peroxisome proliferator
activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-
rich particles from plasma by activating lipoprotein lipase and reducing production of
apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size
and composition of LDL from small, dense particles, to large buoyant particles. These
larger particles have a greater affinity for cholesterol receptors and are catabolized
rapidly.
7.2 Pharmacokinetics of drug:
Absorption:
The absolute bioavailability of the drug cannot be determined as the compound is
virtually insoluble in aqueous media suitable for injection. However, after the drug is
dissolved, it is well absorbed from the gastrointestinal tract.
Peak  plasma  levels  of  Fenofibric  acid  occur  an  average  of  3-8  hours  after
administration.
Effect of Food on Absorption
The drug is insoluble in water and its bioavailability is optimized when taken
with meals. The extent of absorption of (AUC) is comparable between fed and fasted
conditions.
Food increases the rate of absorption of the drug approximately 55%.
Distribution
Volume of distribution is 30L.
Serum protein binding was approximately 99% bound to plasma proteins
Metabolism:
Following oral administration, drug is rapidly hydrolyzed by esterases to the
active  metabolite;  no  unchanged  drug  is  detected  in  plasma  of  healthy  subjects
following  drug  administration.  Active  metabolite  is  primarily  conjugated  with
glucuronic acid and then excreted in urine. A small amount of active metabolite is
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reduced  at  the  carbonyl  moiety  to  a  benzhydrol  metabolite  which  is,  in  turn,
conjugated with glucuronic acid and excreted in urine.
In  vivo  metabolism  data  indicate  that  neither  drug  nor  active  metabolite
undergo oxidative metabolism (e.g.cytochrome P450) to a significant extent.
Excretion:
After  absorption,  drug  is  mainly  excreted  in  the  urine  in  the  form  of
metabolites.
After  administration  of  radiolabeled  drug,  approximately 60% of  the  dose
appeared in the urine and 25% was excreted in the feces.
Active metabolite is  eliminated with a half-life of approximately 16 hours,
allowing once daily administration.
7.3 Interactions:
7.3.1 Drug interactions:
Table 11:Interactions of drug
Drug Interaction
Acenocoumarol The drug increases the anticoagulant effect
Anisindione The drug increases the anticoagulant effect
Atorvastatin Increased risk of myopathy/rhabdomyolysis
Cerivastatin Increased risk of myopathy/rhabdomyolysis
Dicumarol The drug increases the anticoagulant effect
Fluvastatin Increased risk of myopathy/rhabdomyolysis
Lovastatin Increased risk of myopathy/rhabdomyolysis
Pravastatin Increased risk of myopathy/rhabdomyolysis
Rosuvastatin Rosuvastatin possibly increases the effect of the drug
Simvastatin Increased risk of myopathy/rhabdomyolysis
Warfarin The drug increases the anticoagulant effect
60
                                                       Drug profile and API charecterization
           7.3.2 Food interactions:
Food increases the rate of absorption of the drug.
7.4 Indications and usage:
Drug is  a  lipid  regulating  agent  indicated  as  adjunctive  therapy to  diet  to
reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in
adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson
Types IIa and IIb). Drug is also indicated as adjunctive therapy to diet for treatment of
adult  patients  with  hypertriglyceridemia  (Fredrickson  Types  IV  and  V
hyperlipidemia). Fenofibricacid, the active metabolite of drug, produces reductions in
total  cholesterol,  LDL  cholesterol,  apolipoprotein  B,  total  triglycerides  and
triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with
drug results in increases in high density lipoprotein (HDL) and apoproteins apoAI and
apoAII.
It is used alone or in conjunction with statins.
7.4.1 Contraindications:
Drug is  contraindicated  in  patients  who  exhibit  hypersensitivity  to  it.  
It  is contraindicated in patients with hepatic or severe renal dysfunction, including
primary  biliary  cirrhosis,  and  patients  with  unexplained  persistent  liver  function
abnormality.  
It is contraindicated in patients with preexisting gallbladder disease
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7.4.2 Side effects:
 constipation;
 dizziness or lightheadedness;
 fatigue;
 flu-like symptoms;
 gas;
 headache;
 infection;
 joint pain;
 muscle pain or tenderness;
 rashes;
 runny nose;
 stomach pain;
 upset stomach;
 weakness
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7.5. Drug Analysis
  7.5.1. Determination of λmax
Procedure: 
100mg  of  pure  drug  was  taken  and  known  concentration  of  drug  solution  was
prepared by solubilizing in methanol then suitably diluting drug solution in water containing
0.5% sodium lauryl  sulphate.  The  solutions  were  scanned  from 200-400 nm against  the
reagent blank to fix absorption maxima. Spectrum of the Fenofibrate was obtained and λmax of
Fenofibrate was found to be 290 nm. Hence all further investigations were carried out at the
same wavelength.
 7.5.2. Procedure for Calibration curve  
A)  Preparation  of  0.5%  sodium  lauryl  sulphate  solution:  5.0  gms  of  sodium  lauryl
sulphate was weighed and added to required quantity of water with slow and continuous
stirring for dissolving and to avoid formation of large amount of foam. The prepared solution
was sonicated for 45min for complete solubilization of sls in water-
Calibration Curve of Fenofibrate in water
Solutions: 1) Standard Stock -1mg/ml in water+0.5% sls dissolution medium
2)  Working  Stock  -  100mcg/ml  in  water+0.5%  sls  dissolution
medium 
Procedure for plotting standard plot and estimation of drug in   by Double Beam UV
Spectrophotometer
 
From the working stock solution,  different  aliquots  were  taken in series of  10mL
volumetric  flasks  and  volume  made up  with  buffer  to  get  a  series  of  working  standard
solutions  of  concentrations,  2µg/ml,  4µg/ml,  6µg/ml,  8µg/ml  10µg/ml  and  12µg/ml.  The
absorbance  of  samples  was  obtained  spectrophotometrically  against  the  reagent  blank  at
290nm.  The calibration curves were constructed by plotting drug concentration versus the
absorbance value at 290 nm and the regression equation was computed. 
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7.5.3. Particle size determination: Dry sieve analysis for particle size determination
Dry  Sieving  Method— each  test  sieve  was  sieved  to  the  nearest  0.1  g.  An  accurately
weighed  quantity  of  test  specimen  was  placed  on  the  top  (coarsest)  sieve,  and  lid  was
replaced.  The  nest  of  sieves  was  agitated  for  5  minutes.  Then  each  sieve  was  carefully
removed from the nest without loss of material. Each sieve was reweighed, and the weight of
material on each sieve was determined. The weight of material in the collecting pan was also
determined in  a  similar  manner.  The nest  of  sieves  were  reassembled and agitated for  5
minutes. Each sieve was removed and weighed, as previously described. Upon completion of
the analysis, the weights of material were reconciled. Total losses must not exceed 5% of the
weight of the original test specimen. 
Principles of Analytical Sieving— Analytical test sieves are constructed from a woven-wire
mesh, which is of simple weave that is assumed to give nearly square apertures and is sealed
into the base of an open cylindrical container. The basic analytical method involves stacking
the sieves on top of one another in ascending degrees of coarseness, and then placing the test
powder on the top sieve. 
The nest of sieves is subjected to a standardized period of agitation, and then the
weight of material retained on each sieve is accurately determined. The test gives the weight
percentage of powder in each sieve size range. This sieving process for estimating the particle
size distribution of a single pharmaceutical powder is generally intended for use where at
least 80% of the particles are larger than 75 µm. The size parameter involved in determining
particle size distribution by analytical sieving is the length of the side of the minimum square
aperture through which the particle will pass.
PSD of API and solid dispersions were determined using a stack of metal  sieve
plates from the largest to the finest aperture in the following order: 500, 355, 250, 180, 125,
63 and 45 µm. Retsch apparatus type AS 200 basic was used for the analysis. The weight of
the powders  retained on the surface of  each sieve plate  was divided by the total  sample
weight to obtain the corresponding weight percentage oversize for each sieve fraction.
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7.5.4. Solubility studies
Solubility studies were performed by taking drug in 250 mL of buffer and subjected to
mechanical shaking at 200 rpm for 2 hrs. The resultant dispersions were collected and filtered
through 0.2 µ  filters and the concentration of drug was determined from absorbance at 290
nm. The solubility was performed at various pH conditions pH 1.2, pH 4.5,  pH 6.8, pH 7.4
and water. 
7.5.5 DSC thermogram of Fenofibrate: The solid state characteristics of drugs are known
to potentially exert a significant influence on the  solubility parameter. The utility of solid-
state  spectroscopy for  characterization  of  polymorphic  systems  is  becoming  exceedingly
important. 
Polymorphs and/or solvates of a pharmaceutical solid can have different chemical and
physical properties such as melting point, chemical reactivity, apparent solubility, dissolution
rate, optical and electrical properties, vapor pressure, and density. These properties can have a
direct impact on the process-ability of drug substances and the quality/performance of drug
products, such as stability, dissolution, and bioavailability.
Polymorphic studies of drug and selected carrier were performed by DSC. Melting point of
drug, nature of carrier can be determined by this technique. The polymorphic form of drug,
carrier were studied. The samples were taken separately in a pierced aluminium crucible with
a capacity of  40µL and evaluated in METTLER TOLEDO 822e  equipment using eSTAR
software in temperature range of 25-325º C at a heating rate of 10 º C/min with a stream of
nitrogen . The thermograms were recorded.
7.5.6. X-Ray Diffraction study of Fenofibrate
Crystallinity of the drug was determined using the Bruker D8 Advance XRD with
copper target. The conditions were: 40 Kv voltages; 40 mA current; at room temperature. The
drug was loaded on to the diffractometer and scanned over a range of 2θ values from 30 to 450
at a scan rate of 0.1 0 /sec.
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7.5.7. Fourier Transform Infra Red spectrum of Fenofibrate
FTIR was performed by KBr pellet method. Drug and KBr were taken in 1:100 ratio
and ground in mortar for even distribution of sample and KBr. Then it was prepared in the
form of disk by applying pressure of 5 tons for 5 min using a hydraulic press and subjected to
IR. The software used was spectrum (version 6.1.0) in the wave number range of 400-4000
cm -1. The resolution is 4 cm -1.
7.5.8. Powder and Flow Properties of API (USP NF 2009).
A) Bulk density:
Bulk density was  determined  by measuring the  volume of  a  known mass  of  powder
sample that has been passed through a screen into a graduated cylinder (USP Method I).
Approximately 10  gms of  test  sample,  M was  introduced  into  25  ml  dry measuring
cylinder without compacting. The powder was leveled carefully without compacting and read
the unsettled apparent volume V0, to the nearest graduated unit. Bulk density was calculated,
in g per ml, by the formula.
(M) / (Vo)
Generally replicate determinations are desirable for the determination of this property.
B) Tapped density:
Tapped  density  was  achieved  by  mechanically  tapping  a  measuring  cylinder
containing a powder sample. After measuring the initial weight and volume, the cylinder was
mechanically tapped, and volume readings were taken until little further volume change is
observed. 
Procedure: Cylinder containing the sample was tapped mechanically by raising the cylinder
and allowing it to drop under its own weight using a suitable mechanical tapped density tester
that provides a fixed drop of 14 ± 2 mm at a nominal rate of 300 drops per minute. Unless
otherwise specified, the cylinder was tapped 500 times initially and the tapped volume was
measured,  Va, to the nearest graduated unit. The tapping was repeated for an additional 750
times and the tapped volume was measured, Vb, to the nearest graduated unit. If the difference
between the two volumes is less than 2%, Vb is the final tapped volume, Vf . It was repeated in
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increments of 1250 taps, as needed, until the difference between succeeding measurements is
less than 2%. The tapped density was calculated, in g per mL, by the formula: 
(M) / (Vf).
Generally replicate determinations are desirable for the determination of this property.
C) Compressibility Index: 
The  Compressibility  Index and  Hausner  Ratio are  measures  of  the  property  of  a
powder  to  be  compressed.  As  such,  they  are  measures  of  the  relative  importance  of
interparticulate interactions. In  a free-flowing powder,  such interactions are generally less
significant,  and the bulk and tapped densities will be closer in value. For poorer flowing
materials,  there  are  frequently  greater  interparticle  interactions,  and  a  greater  difference
between the bulk and tapped densities will be observed. These differences are reflected in the
Compressibility Index and the Hausner Ratio. 
Compressibility Index— Calculate by the formula: 
CI (%) =     Vo-Vf  x 100
   Vo 
Hausner Ratio— Calculate by the formula: 
HR =       Vf  
     Vo 
         
Where V0   -   Bulk volume 
      Vf   -   Tapped volume
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  Table 12: Scale of Flowability (USP)
Compressibility Index (%) Flow Character Hausner’s Ratio
≤ 10 Excellent 1.00-1.11
11-15 Good 1.12-1.18
16-20 Fair 1.19-1.25
21-25 Passable 1.26-1.34
26-31 Poor 1.35-1.45
32-37 Very Poor 1.46-1.59
> 38 Very, very Poor > 1.60
D) Determination of Angle of Repose
The angle of repose has been used to characterize the flow properties of solids. Angle
of  repose is  a  characteristic  related  to  interparticulate  friction or  resistance to  movement
between particles.
Angle of repose was formed on a fixed base with a retaining lip to retain a layer of
powder on the base. The base should be free of vibration. The height of the funnel was varied
to carefully build up a symmetrical cone of powder. Care should be taken to prevent vibration
as the funnel is moved. The funnel height should be maintained approximately 2–4 cm from
the top of the powder pile as it is being formed in order to minimize the impact of falling
powder on the tip of the cone. If a symmetrical cone of powder cannot be successfully or
reproducibly prepared, this method is not appropriate. Angle of repose was determined by
measuring the height of the cone of powder and calculating the angle of repose, from the
following equation: 
tan α = h/r
Table 13: Flow Properties and Corresponding Angle of Repose
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Flow Property Angle of Repose (degrees)
Excellent 25–30
Good 31–35
Fair—aid not needed 36–40
Passable—may hang up 41–45
Poor—must agitate, vibrate 46–55
Very poor 56–65
Very, very poor >66
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VIII. Excipient profile
 POVIDONE
Nonproprietary 
Names
• BP: Povidone, JP: Povidone, PhEur: Povidonum USP: Povidone
Synonyms
E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; 
polyvidone; ,polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer
Empirical 
formula
(C6H9NO)n
Molecular 
weight
2500–3000 
Description
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. 
Functional 
categories
Disintegrant; dissolution aid; suspending agent; tablet binder.
Solubility
freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water; 
Melting point Softens at 150°C.
Stability and 
storage 
conditions
Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it 
should be stored in an airtight container in a cool, dry place.
Incompatibilities
It forms molecular adducts in solution with sulfathiazole, sodium salicylate, 
salicylic acid, phenobarbital, tannin, and other compounds.
Applications
Povidone solutions may also be used as coating agents and  it is also used as a
suspending, stabilizing, or viscosity-increasing agent In tableting, povidone 
solutions are used as binders in wet-granulation.
Table no. 14 profile of povidone
 MANNITOL
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Nonproprietary
Names
• BP: Mannitol, JP: D-Mannitol,PhEur: Mannitolum, USP: Mannitol
Synonyms
Ordycepic  acid;  C*PharmMannidex;  E421;  manna  sugar;  D-mannite;
mannite; Mannogem; Pearlitol.
Empirical
formula
C6H14O6
Description
Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is
isomeric  with  sorbitol.  Mannitol  occurs  as  a  white,  odorless,  crystalline
powder, or free-flowing granules. 
Functional
categories
Diluent;  diluent  for  lyphilized  preparations;  sweetening  agent;  tablet  and
capsule diluent; tonicity agent.
Melting point 166–168°C
Density 1.514 g/cm
3
Stability  and
storage
conditions
Mannitol  is  stable  in  the  dry  state  and  in  aqueous  solutions.  In  solution,
mannitol is not attacked by cold, dilute acids or alkalis, nor by atmospheric
oxygen in the absence of catalysts The bulk material should be stored in a
well-closed container in a cool, dry place. 
Incompatibility
Mannitol  solutions,  20% w/v or stronger,  may be salted out by potassium
chloride or sodium chloride. Reducing sugar impurities in mannitol have been
implicated  in  the  oxidative  degradation  of  a  peptide  in  a  lyophilized
formation.  
Applications
Used as a  diluent (10–90% w/w) in tablet  formulations,  Mannitol  may be
used in  direct-compression tablet  applications,  for  which  the  granular  and
spray-dried forms are available.
Table no. 15:  profile of mannitol
  
MAGNESIUM STEARATE
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Nonproprietary 
Names
BP: Magnesium Stearate,
JP: Magnesium Stearate ,
PhEur: Magnesium Stearate ,
USP-NF: Magnesium Stearate
Synonyms
Dibasic magnesium stearate; magnesium distearate; magnesiistearas; 
magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic 
acid, magnesium salt; Synpro 90
Empirical 
formula C36H70MgO4
Molecular
 weight
591.24
Description
Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic 
acid and a characteristic taste. The powder is greasy to the touch and 
readily adheres to the skin.
Functional 
categories
Tablet and capsule lubricant.
Solubility
Practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%).
Melting point 117–150 oC
Density 1.092 g/cm3
Loss on drying 46.0%
Stability and 
storage 
conditions
Magnesium stearate is stable and should be stored in a well-closed 
container in a cool, dry place.
Incompatibilitie
s
Incompatible  with  strong  acids,  alkalis,  and  iron  salts.  Avoid  mixing
with strong oxidizing materials.
Applications It is primarily used as a lubricant in capsule and tablet manufacture.
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HYDROXYPROPYL METHYL CELLULOSE:
Nonproprietary
Names
• BP: Hypromellose
• JP: Hydroxypropylmethylcellulose
• PhEur: Hypromellosum
• USP: Hypromellose
Synonyms Benecel  MHPC;  E464;  hydroxypropyl  methylcellulose;  HPMC;  Methocel;
methylcellulose  propylene  glycol  ether;  methyl  hydroxypropylcellulose;
Metolose; Tylopur.
Description
Hypromellose is an odorless and tasteless, white or creamy white fibrous or
granular powder.
Functional
categories
Coating  agent;  film-former;  rate-controlling  polymer  for  sustained  release;
stabilizing agent; suspending agent; tablet binder; viscosity-increasing agent.
Solubility
soluble  in  cold  water,  forming  a  viscous  colloidal  solution;  practically
insoluble in chloroform, ethanol(95%), and ether, but soluble in mixtures of
ethanol and dichloromethane, mixtures of methanol and dichloromethane, and
mixtures of water and alcohol. Certain grades of hypermellose are soluble in
aqueous acetone solutions, mixtures of dichloromethane and propan-2-ol, and
other organic solvents
Melting point
browns at 190–2000C; chars at 225–2300C.Glass transition temperature is 170–
1800C.
Stability  and
storage conditions
Hypromellose powder  is  a  stable material,  although it  is  hygroscopic  after
drying. Solutions are stable at pH 3–11. Increasing temperature reduces the
viscosity of solutions. Hypromellose powder should be stored in a well-closed
container, in a cool, dry place.
Incompatibilities Hypromellose is incompatible with some oxidizing agents.
Applications
as a matrix for use in extended-release tablet formulations used to enhance the
aqueous solubility of poorly soluble compounds by making solid dispersions.
Table no. 17:  profile of HPMC
SOLUPLUS:
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Nonproprietary
Names
Graft co polymer
Molecular
weight
90 000 – 140 000g/mol
Description
Soluplus is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft
co-polymer (13/57/30). It is a free flowing white to slightly yellowish granule
with faint characteristic odour.
Functional
categories
used in film casting, used in capsule formation, as a binder in wet granulation
or dry binder in direct compression, drug layering, and as emulsifier
Solubility
It is soluble in water. It is also soluble in acetone (up to 50%), methanol (up to
45%), ethanol (up to 25%) and dimethyformamide (up to 50%)
Glass  transition
temperature
Approximately  700c
Stability  and
storage
conditions
It should be closed in tightly closed container.
Applications
Soluplus is used to increase solubility of poorly soluble drugs, used in extrude
formation,  
Table no. 18: profile of soluplus
KOLLICOAT IR
Synonyms Polyvinyl alcohol-polyethylene glycol copolymer.
Molecular weight about 45,000 Daltons
Description free-flowing powder, colorless, white, very faint odour
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Viscosity  (20  %
solution)
115 mPas
Composition Ethanol, polymer with .alpha.-hydro-.omega.-hydroxy poly(oxy-1,2-ethanediyl)CAS-No. 96734-39-3
Functional
categories
Coating agent; film-former; tablet binder;., Dissolution enhancer
Solubility
Solubility water > 50 %
0.08 N HCI > 50 %
phosphate buffer pH 6.8 > 50 %
pH (20 % solution) 6.7
Melting point Melting temperature 209 °C
Stability  and
storage conditions
Store in cool place. Keep container tightly closed in a dry and well-ventilated
place. Provide appropriate exhaust ventilation at places where dust is formed.
Normal measures for preventive fire protection.
Incompatibilities
Strong oxidizing agents.
Applications
as a matrix for use in immediate-release tablet formulations. used to enhance
the  aqueous  solubility  of  poorly  soluble  compounds  by  making  solid
dispersions.
Table no. 19: profile of kollicoat
SORBITOL
Synonyms glucitol, Sorbogem® and Sorbo
Molecular weight 182.17 g mol−1
Molecular
formula
C6H14O6
Description free-flowing powder, colorless, white, very faint odour
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Density 1.489 g/cm³
Composition sugar alcohol that the human body metabolizes slowly. It  can be obtained by
reduction of glucose, changing the aldehyde group to a hydroxyl group
Functional
categories
Sweetner, laxative, Humectant, thickener
Solubility Easily soluble in cold water, hot water.
Melting point 95 °C, 368 K, 203 °F
Boiling point 296 °C, 569 K, 565 °F
Stability  and
storage conditions
Keep container  dry.  Keep in a  cool place.  Ground all  equipment containing
material. Keep container tightly closed. Keep in a cool, well-ventilated place.
Combustible materials should be stored away from extreme heat and away from
strong oxidizing agents..
Incompatibilities
Strong oxidizing agents.
Applications Sweetner, humectant and thickener in health care, food and cosmetics
POLYPLASDONE XL 
Synonyms Crospovidone, Polyvinylpyrrolidone.
Molecular weight about 45,000 Daltons
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Description Non-ionic, crosslinked, White, free flowing, compressible powder
pH(10 %slurry) 5.0 – 8.0
Composition A synthetic homopolymer of cross-linked N-vinyl-2-pyrrolidone.
Functional
categories
Disintegrant, Solubilizer
Solubility
Completely  insoluble  in  water,  acids,  alkalis,  and  all  organic  solvents.
Hygroscopic. Swells rapidly in water. Rapidly disperses in water, but does not
gel even after prolonged exposure.
Melting point Not available
Stability  and
storage conditions
Store in cool place. Keep container tightly closed in a dry and well-ventilated
place. Provide appropriate exhaust ventilation at places where dust is formed.
Normal measures for preventive fire protection.
Incompatibilities
Strong oxidizing agents.
Applications
Super disintegrant and dissolution aid in wet granulation, dry granulation and
direct compression.
Table no. 21: profile of PPXL
HYDROXY PROPYL CELLULOSE (SSL)
Synonyms Cellulose, 2-hydroxypropyl ether; oxypropylated cellulose.
Molecular weight Variable
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Description  White, free flowing, compressible powder
Viscosity Lowest viscosity, varies based on the specific use
Composition Nisso  HPC  consists  of  hydroxypropyl  ethers  obtained  by  the  reaction  of
cellulose with propylene oxide.
Functional
categories
It is used as a topical ophthalmic protectant and lubricant.
Solubility Soluble in both water and organic solvents.
Melting point Variable
Stability  and
storage conditions
Store in cool place. Keep container tightly closed in a dry and well-ventilated
place. Provide appropriate exhaust ventilation at places where dust is formed.
Normal measures for preventive fire protection.
Incompatibilities
Strong oxidizing agents.
Applications available for food use as a fat substitute, whipping aid, emulsion aid, and for
film coating and tablet binding. 
.
Table no. 22: profile of HPC SSL
LACTOSE MONOHYDRATE
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Nonproprietary Names
BP: Lactose monohydrate
PhEur: Lactosum monohydricum
JP: Lactose
USPNF: Lactose monohydrate
Synonyms
CapsuLac;  GranuLac;  Lactochem;  lactosum
monohydricum;Monohydrate; Pharmatose; PrismaLac; SacheLac;
SorboLac;SpheroLac; SuperTab 30GR; Tablettose
Empirical formula C12H22O11_H2O 
Molecular weight 360.31
Description Lactose  occurs  as  white  to  off-white  crystalline  particles  orpowder. Lactose is odorless and slightly sweet-tasting
Functional categories Binding  agent;  diluent  for  dry-powder  inhalers;  tablet  binder;tablet and capsule diluent.
Solubility
Chloroform Practically insoluble
Ethanol Practically insoluble
Ether Practically insoluble
Water 1 in 5.24
           1 in 3.05 at 400C
           1 in 2.30 at 500C
           1 in 1.71 at 600C
           1 in 0.96 at 800C
Melting point 201–202
0C
Density 1.545 g/cm3
Loss on drying 40.5%
Stability and storage 
conditions
Mold  growth  may occur  under  humid  conditions  (80% relative
humidity and above). 
Lactose may develop a brown coloration on storage, the reaction
being accelerated by warm, damp conditions. 
Solutions show mutorotation.
Lactose should be stored in a well-closed container in a cool, dry
place.
Incompatibilities
A Millard-type condensation reaction is likely to occur
between lactose and compounds with a primary amine group to
form brown, or yellow-brown-colored products.
Lactose  is  also  incompatible  with  amino  acids,  aminophylline,
amphetamines, and lisinopril.
Applications
Lactose is widely used as a filler or diluent in tablets and
capsules, and to a more limited extent in lyophilized products and
infant formulas.
Table no. 23:  profile of lactose
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IX. METHODOLOGY
9.1. Formulation Development of Solid Dispersions
A).Preparation of Solid Dispersion by Solvent Evaporation Technique: 
The carriers used in the study were soluplus, PVP K90, HPMC 3cps, kollicoat
IR, HPS SSL. In the preparation of solid dispersion by solvent evaporation method, solvent
used was methanol which dissolves both drug and carriers.
Solid dispersions were prepared in drug/carrier concentrations of 1:1, for drug:
soluplus/  PVP K90/  HPMC 3cps/  kollicoat  IR/  HPS SSL and  after  characterization drug
carrier concentrations of 1:0.5, 1:1,1:2, 1:3, 1:4 for drug : HPMC 3cps and soluplus were
prepared. Drug is initially dissolved in solvent and then carriers were added to the solution
under  stirring  conditions.  Then  the  solvent  is  subjected  to  evaporation.  After  complete
evaporation of the solvent, solid dispersion is collected, milled, dried and passed through 60#
size. The obtained solid dispersions were further characterized for drug content, Solubility
studies and DSC
B).Preparation of Solid Dispersion by Melt fusion Technique:
Solid dispersions were prepared in drug/carrier concentrations of 1:0.5, 1:1, 1:2, 1:3, 1:4
for drug: HPMC 3cps and drug: soluplus. Melt fusion is carried out in an oil bath. Drug and
polymer  in  specific  ratios  are  initially premixed  and  sifted  through  sieve  no  40  and  the
mixture is transferred in to the oil bath. 
The temperature was set above the melting point of drug and the mixture was continuously
mixed at that temperature until drug melts and completely dispersed in the polymer
The resulting mixture in the glassy state was subjected to quench cooling in an ice bath and
the dispersion is milled, dried and sifted through sieve no 60. The obtained solid dispersions
were further characterized for drug content, Solubility studies and DSC
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Table 24: Composition of solid dispersions
Formulation code            Carrier Ratios
SD1 Drug: PVP K90 1:1
SD2 Drug: soluplus 1:1
SD3 Drug: kollicoat IR 1:1
SD4 Drug: HPC SSL 1:1
SD5 Drug: HPMC 3cps 1:1
SD6 Drug: soluplus 1:0.5
SD7 Drug: soluplus 1:1
SD8 Drug: soluplus 1:2
SD9 Drug: soluplus 1:3
SD10 Drug: soluplus 1:4
           SD 11 Drug: soluplus fusion
method
1:0.5
           SD 12 Drug: soluplus fusion
method
1:1
           SD 13 Drug: soluplus fusion
method
1:2
           SD 14 Drug: soluplus fusion
method
1:3
           SD15 Drug: soluplus fusion
method
1:4
           SD16 Drug: HPMC 3cps 1:0.5
SD17 Drug: HPMC 3cps 1:1
SD18 Drug: HPMC 3cps 1:2
SD19 Drug: HPMC 3cps 1:3
SD20 Drug: HPMC 3cps 1:4
            SD21 Drug: HPMC 3cps
fusion method
1:0.5
SD22 Drug: HPMC 3cps
fusion method
1:1
SD23 Drug: HPMC 3cps
fusion method
1:2
SD24 Drug: HPMC 3cps
fusion method
1:3
SD25 Drug: HPMC 3cps
fusion method
1:4
         
9.2. CHARACTERIZATION OF SOLID DISPERSIONS
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9.2.1. Drug content estimation
100mg of pure drug was taken and dissolved in approximately 3 ml of methanol. The
solution was filtered and the volume of solution was made up with water containing sls,
suitably  diluted  with  buffer  and  drug  content  was  analyzed  against  blank  by  UV
spectrophotometer at 290nm. Solid dispersions equivalent to 100 mg of drug was transferred
to a separate volumetric flask and dissolved in methanol and filtered. Required amount of
water was added to the filtrate, suitably diluted and drug content was analyzed against blank
by UV spectrophotometer at 290 nm. The percentage of drug present in the solid dispersion
was calculated.
. 
9.2.2. Solid state characterization of solid dispersion by Differential Scanning 
Calorimetry (DSC)
The solid dispersions were taken in an pierced aluminium crucible with a capacity of 
40µL and evaluated in METTLER TOLEDO equipment using eStar software (version 9.10 ) 
in a temperature range of 25-325º C at a heating rate of 10 º C/min under a stream of 
nitrogen. The thermograms were recorded.
9.2.3. Solubility studies
Solubility studies were performed for those solid dispersions that have shown a change in the
polymorphic structure  (crystalline state to amorphous state) by taking solid dispersions of
drug and various carrier ratios  in 250 mL of water and buffers of pH 1.2, pH 4.5, pH 6.8, pH
7.4   buffer  and  subjected  to  mechanical  shaking  at  200  rpm  for  2  hrs.  The  resultant
dispersions were collected and filtered through 0.2 µ filters and the concentration of drug was
determined from absorbance at 290 nm. The solid dispersion ratio was optimized based on
the solubility studies performed at various pH conditions
9.2.4. Solid state characterization by X-Ray Diffraction Studies (XRD):
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Crystallinity of the samples was determined using the Bruker D8 Advance Analytical
with  copper  target.  Samples  were  properly  ground  and  uniformly  spread  in  the  sample
holders made of PMMA (8.5 mm, φ25mm, 1mm depth, airtight). The samples were loaded on
to the diffractometer and scanned over a range of 2-Theta values from 30 to 450 at a scan rate
of 0.10 /sec. 
Powder XRD patterns of Fenofibrate,  HPMC 3pcs,  and optimized solid dispersion
and  stability  sample  exposed  to  400C  &  75%  RH  for  1  month  were  recorded  using
diffractograms (Bruker) and Cu-kα radiation. 
. 
9.2.5. Investigation of chemical interaction between drug and carrier in solid dispersion
by FTIR:
Studies of drug matrix interaction have a substantial impact on stability and solubility
of solid dispersion. Hydrogen bonding between drug and carrier increases the stability of
drug in the matrix. The interaction between drug and carrier in solid dispersion were studied
by  FTIR  spectroscopy  (Perkin  Elmer  FT‐IR  410).  FTIR  was  performed  by  KBr  pellet
method. Drug and KBr were taken in 1:100 ratio and ground in mortar for even distribution
of sample and KBr. Then it was prepared in the form of disk by applying pressure of 5 tons
for 5  min using a hydraulic press and subjected to  IR.  The software used was spectrum
(version 6.1.0) in the wave number range of 400-4000 cm -1. The resolution is 4 cm -1. 
                             9.3 STABILITY STUDIES OF SOLID DISPERISON
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The purpose of stability testing is to provide evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental
factors, such as temperature, humidity, and light, and to establish a retest period for the drug
substance or a shelf life for the drug product and recommended storage conditions.
Table 25: Stability studies, storage conditions and duration of study
Study Storage condition Minimum time period covered 
by data at submission
Long-term* 25ºC + 2º C/60% RH + 5% RH
or
30ºC + 2º C/65% RH + 5% RH
12 months
Intermediate*
*
30ºC + 2º C/65% RH + 5% RH 6 months
Accelerated 40ºC + 2º C/75% RH + 5% RH 3 months
*       It is up to the applicant to decide whether long term stability studies are preformed at 
   25ºC + 2º C/60% RH + 5% RH or 30ºC + 2º C/65% RH + 5% RH.
** If 30ºC + 2º C/65% RH + 5% RH is the long-term condition, there is no intermediate condition.
Before subjecting to stability studies, solid dispersion samples were analyzed by DSC,
FTIR and XRD studies and initial thermograms and spectra were recorded. Then samples
were subjected to accelerated conditions, 40ºC  + 2º C/75% RH  + 5% RH. After 4 weeks,
DSC thermograms, FTIR and XRD patterns of solid dispersion samples were recorded and
compared with initial thermograms and spectra of respective samples.
9.4. PREFORMULATION STUDIES OF TABLET
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Preformulation testing is an investigation of physical  and chemical properties of a
solid dispersion alone and when combined with excipients. It is the first development in the
rationale development of the dosage forms.
Preformulation studies yield necessary knowledge to develop suitable formulation. It
gives information needed to define the nature of the drug substance and provide a dosage
form. Hence, the following pre-formulation studies were performed for the obtained sample
of drug.
9.4.1. Physical characterization of solid dispersion.
The  solid  dispersion  was  characterized  for  its  physical  properties  such  as  its
appearance, density, flow properties, particle size distribution and solubility.
a).Particle size distribution:
Particle Size Determination (PSD) of blends of 12 formulations was determined by
Retsch apparatus type AS 200.
9.4.2. Drug-Excipients compatibility studies:
A small amount of physical mixture of the solid dispersion and excipients was placed
in a vial, and rubber stopper was placed on the vial and sealed properly. After storage for a
period of 4 weeks at 40°C / 75% RH, the sample was observed physically for any changes by
comparing with the initial physical mixture.
Table 26:  Excipient Compatibility Studies
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9.5. Formulation studies
9.5.1. Development Strategy:
Following ingredients were selected for formulation development of solid dispersion
based on the literature search and preformulation studies.
Each Batch size: 150 Tablets.
Manufacturing Process:
1. Solid  dispersion  and  Mannitol/  Lactose  (low  moldable  saccharides)  and
polyplasdone were accurately weighed individually.
2. Solid dispersion and polymer and ppxl were then mixed well to form uniform blend.
3. The  above  blend  was  granulated  using  water/  ethanol  as  granulating  fluid  and
sorbitol (High moldable saccharide) as the binding agent.
4. The granulated mass was then dried and milled using a quadraco mill 40G at speed
30 Hz.
5. Extragranular part (magnesium stearate) was weighed.
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Ingredients Ratio Code
1 Solid dispersion -- A
2 Solid dispersions  + Mannitol  1:1 B
3 Solid dispersions  +  Sorbitol 1:1 C
4 Solid dispersions +  Lactose 1:1 D
5 Solid dispersions+ Polyplasdone xl 1:1 E
6 Solid dispersions  + Mg Stearate 1:1 F
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6.  Step 5 part was added to the step 4 granules and mixed uniformly.
7. The  blend  was  then  compressed  into  tablets  using  suitable  punch  (10mm)  and
compression machine.
8. Tablets  were  subjected  to  various  moisture  conditions  for  moisture  treatment  to
attain sufficient hardness and DT. 
Formulation F1 
(mg/tablet
)
%w/w F2 
(mg/tablet)
%w/w F3 
(mg/tablet
)
%w/w
Solid dispersion 160 160 160
Mannitol 166.5 166.5 -
Lactose - - 166.5
Sorbitol 18.5 18.5 18.5
Polyplasdone XL - -
Magnesium
sterate
5 5 5
Water        qs - -
Ethanol          - qs qs
Total Weight 350 350 350
Table no. 27:  Formulation F1 to F3
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Formulation F4 
(mg/tablet)
%w/w F5 
(mg/tablet)
%w/w F6
(mg/tablet)
%w/
w
Solid dispersion 160 160 160
Mannitol 162 157.5 153
Lactose - - -
Sorbitol 18 17.5 17
Polyplasdone XL 5 10 15
Magnesium
sterate
5 5 5
Water - - -
Ethanol qs qs qs
Total Weight 350 350 350
Table no. 28:  Formulation F4 to F6
9.6 EVALUATION PARAMETERS
9.6.1 Blend Characterization
Blend  Characterization  parameters  such  as  bulk  density,  tapped  density,
Compressibility Index, Hausner’s ratio, Angle of Repose were performed and computed to 12
formulations of trial batches. 
Particle Size Determination (PSD) of blends of 6 formulations was determined by
Retsch apparatus type AS 200.
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9.7 MOISTURE UPTAKE STUDIES OF THE TABLETS
Moisture  treatment  is  the  main  step  in  the  formulation  of  the  tablets  by  WOWTAB
technology
The tablets are compressed at a very low hardness of 1 to 2 KP. The mechanical strength of
the tablets was substantially increased after moisture treatment and moisture treatment also
has a negative influence on disintegration time which is of main role in orodispersible tablets.
Various super saturated salt solutions are used for attaining specific relative humidity values.
Three  different  relative  humidities  have  been  selected  to  study  the  effect  of  moisture
treatment on hardness and disintegration time of the tablet 
SALT BATH PUBLISHED RH AT 25°C
LITHIUM BROMIDE 6.37%
LITHIUM CHLORIDE 11.30%
POTASSIUM ACETATE 22.51%
MAGNESIUM CHLORIDE 32.80%
POTASSIUM CARBONATE 43.16%
MAGNESIUM NITRATE 52.89%
SODIUM BROMIDE 57.57%
POTASSIUM IODIDE 68.86%
SODIUM CHLORIDE 75.30%
POTASSIUM CHLORIDE 84.34%
POTASSIUM SULFATE 97.30%
*Based on: Humidity Fixed Points of  Binary  Saturated Aqueous Solutions
Table no. 29:  salts for moisture treatment
9.7.1 Preparation of super saturated Magnesium chloride solution (33%RH)
Take 100ml of water and magnesium chloride is added to it slowly with stirring and
the addition is continued until the liquid is completely saturated and excess amount of salt
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added gets settled at the bottom of the container.
Care should be taken regarding the temperature of the solvent during addition of salt
because high temperature may increase the solubility of the salt.
The  super  saturated  solution  was  placed  at  the  bottom of  the  dessicator  and  the
chamber lid is tightly closed by applying wax at the brim so that the chamber retains the
moisture.
9.7.2 Preparation of super saturated Magnesium nitrate solution (53%RH)
Take 100ml of water and magnesium nitrate is added to it slowly with stirring and the
addition is continued until the liquid is completely saturated and excess amount of salt added
gets settled at the bottom of the container.
Care should be taken regarding the temperature of the solvent during addition of salt
because high temperature may increase the solubility of the salt.
The  super  saturated  solution  was  placed  at  the  bottom of  the  dessicator  and  the
chamber lid is tightly closed by applying wax at the brim so that the chamber retains the
moisture.
9.7.3 Preparation of super saturated potassium chloride solution (84%RH)
Take 100ml of water and magnesium chloride is added to it slowly with stirring and
the addition is continued until the liquid is completely saturated and excess amount of salt
added gets settled at the bottom of the container.
Care should be taken regarding the temperature of the solvent during addition of salt
because high temperature may increase the solubility of the salt.
The  super  saturated  solution  was  placed  at  the  bottom of  the  dessicator  and  the
chamber lid is tightly closed by applying wax at the brim so that the chamber retains the
moisture.
9.8 MOISTURE TREATMENT
The  tablets  formulated  at  low hardness  of  1  to  2  KP and  the  tablets  are  placed  in  the
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dessicators containing the super saturated salt solutions and the lid is tightly closed and kept
undisturbed for 36 to 48 hrs
Moisture  treatment  for  few tablets  was  continued  till  4  to  5  days  to  find  the  effect  for
prolonged moisture treatment.
Formulation will be optimized based on the hardness and the disintegration time before and
after the moisture treatment
9.9 EVALUATION OF FAST DISINTEGRATING TABLETS (USP 29- NF 34)
All  the  batches  of  tablets  were  evaluated  for  various  physical  parameters  like
thickness,  weight  variation,  friability,  hardness,  drug  content  and  dissolution  as  per
pharmacopoeial standards.
A) Thickness:
Thickness of tablet is important for uniformity of tablet size. Thickness of tablets can
vary with no change in weight because of the difference in the density of the granulation and
the pressure applied to the tablets, as well as the speed of the compression machine.  Ten
tablets  were  randomly  selected  and  thickness  was  measured  using  vernier  calipers  and
recorded. 
B) Weight variation:
20  tablets  were  taken  and  weighed  individually on  a  digital  weighing  balance.
Average weight was calculated and the individual tablet weight was compared to the average.
The tablet passes the U.S.P. test if no more that 2 tablets are outside the percentage limit and
if no tablet differs by more than 2 times the percentage limit. 
Average weight =    Weight of 20 tablets
20
Table 30: Acceptance criteria for tablet weight variation 
Average weight of tablet(mg) % difference allowed
130 or Less than ± 10
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130-324 ± 7.5
More than 324 ± 5
C) Crushing strength:
Tablet requires a certain amount of strength or hardness and resistance to friability to
withstand mechanical shakes of handling in manufacture, packaging and shipping. Hardness
generally measures the tablet crushing strength. Changes in hardness results in differences in
disintegration  and  dissolution  characteristics.  The  crushing  strength  of  the  tablet  was
determined using Schleuniger hardness tester.
D) Friability test:
Ten tablets from each batch were examined for friability using Roche Friabilator and
the equipment was run for 4min at 25 revolutions per minute. The tablets were taken out,
dedusted and reweighted and % friability was calculated. Tablet that loose less than 0.5- 1 %
of the tablet weight were considered acceptable.
%Friability = (Loss in weight / Initial weight) x 100
E) Content uniformity test:
Ten tablets from each formulation were powdered. The powdered sample equivalent
to 100 mg of drug was transferred to a volumetric flask and dissolved in methanol, mixed and
filtered.  Required  amount  of  phosphate  buffer  pH 7.4 was added  to  the  filtrate,  suitably
diluted with media and drug content was analyzed against blank by UV spectrophotometer at
331 nm. The percentage of drug present in the tablets was calculated.
G) Disintegration test
The  time  for  disintegration  of  ODTs  is  generally  less  than  one  minute  and  actual
disintegration  time  that  patient  can  experience  ranges  from  5-30  seconds.  The  standard
procedure of performing disintegration test for these dosage forms has several limitations and
they are not suitable for the measurement of very short disintegration times.  The method
needs to  be modified for  ODTs as  disintegration is  required without  water;  thus  the test
should mimic disintegration in salivary contents. A modified dissolution apparatus is applied
to an ODT with a disintegration time that is too fast to distinguish differences between tablets
when the compendial method is used. A basket sinker containing the tablets is placed just
below the water surface in a container with 900 mL of water at 37 0C, and a paddle rotating at
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100  rpm  is  used.  The  disintegration  time  is  determined  when  the  tablet  has  completely
disintegrated and passed through the screen of the sinker
H) In vitro dissolution studies: 
Dissolution  study  was  conducted  for  optimized  formulation  using  USP  type-II
apparatus (ELECTROLAB). The dissolution test was performed in buffers of different pH
and in water containing 0.5% sodium lauryl sulphate as the dissolution medium at 75 rpm and
at a temperature of 37 0C ± 0.5 0C for one hour. Five milliliters of aliquots were periodically
withdrawn at time intervals of 2, 5, 10, 20, 30, 45, and 60 minutes and the sample volume
was replaced with an equal volume of fresh dissolution medium. The samples were diluted
and analyzed spectrophotometrically at 290nm.
9.9.3. Accelerated Stability study of the optimized batch 
In order to determine the change in evaluation parameters and in vitro release profile
on storage, stability study of optimized batch  was carried out at accelerated storage condition
at temperature 40° ± 2° C and 75% ± 5% RH in a humidity chamber for 1 month. Sample
were withdrawn after 30 days interval and evaluated for change in  physical appearance . 
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X. RESULTS AND DISCUSSION.
10.1 Drug Analysis:
10.1.1. Determination of λmax
     
       
Figure 8: Spectrum of Fenofibrate
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10.1.2. Procedure for Calibration curve  
Calibration Curve of Fenofibrate in water
S.No
Concentration
in mcg/ml
Absorbance
at 290.0nm
1 0 0
2 2 0.129
3 4 0.243
4 6 0.362
5 8 0.486
6 10 0.592
7 12 0.729
Table no. 31:  calibration curve of Fenofibrate
Figure no: 9 calibration curve of Fenofibrate
Inference:  The  λmax of  Fenofibrate  was  found  to  be  290  nm. The  linear  equation  was
A=0.0593 x concentration (mcg/mL) +0.0056 Different  standard  concentrations  and  their
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absorbance values were shown in the table 23. Goodness of fit of regression equation was
supported by regression value of 0.9995 indicating linearity in the absorbance with increase
in concentration.
10.1.3. Particle size determination: 
Dry sieve analysis for particle size determination
Table 32: Particle size determination of Fenofibrate
Sieve
Mesh
Number
Sieve Size
Opening(µm)
Mass of Sample
Retained on Each
Sieve(g)
Percentage of
Sample Retained
on Each Sieve (%)
Cumulative
Percentage of
Sample Retained
on Each Sieve (%)
20 841 0.17 3.4 3.4
40 420 0.02 0.4 3.8
60 250 0.11 2.2 6
80 177 0.36 7.3 13.3
100 149 0.26 5.2 18.5
120 125 0.24 4.8 23.3
Pan - 3.76 76.4 99.7
Inference:  From the particle  size distribution data,  it  was observed that,  99.7 % of  API
particles were found to be below of 12 microns in size.
10.1.4. Solubility studies:
Solubility of drug in different buffers:
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Table 33: Solubility data of pure drug
Medium Solubility(µg/ml)
Water 0.2568
0.1N HCl 0.3637
pH4.5 Acetate buffer 0.2568
pH6.8 Phosphate buffer 0.2184
pH7.4 Phosphate buffer 0.2426
Figure 10: pH Solubility plot of pure drug
Inference:  Solubility studies of pure drug were performed and studies showed that drug is
showing very poor solubility in all the medias. Solubility of drug in different pH conditions
was less than 0.4mcg/ml and the solubility of the drug is not influenced by the changes in the
pH of the media
The uniform solubility pattern of fenofibrate in all the medias was attributed to the lack of
chemically ionisable groups in the structure.
10.1.5 DSC thermogram of Fenofibrate
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Figure 11: Thermogram of API
Inference: Polymorphic studies were performed by DSC for API. The melting range of API
was found to be 78 to 82 º C. The sharp peak in the thermogram of API indicates crystalline
nature of drug.
10.1.6. X-Ray Diffraction study of Fenofibrate
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Figure 12: X RAY DIFFRACTION PATTERN OF FENOFIBRATE
Inference: The X-ray diffractogram of Fenofibrate has sharp peaks at diffraction angles (2θ)
6.689°,  11.482°,  12.707°,  13.352°,  16.898°,  18.078°,  19.054°,  20.059°,  20.400°,  22.386°,
23.110°,  23.789°,  24.03°,  25.353°,  26.835°,  27.417°,  27.864°,  28.454°,  29.337°,
29.904°,31.416°,32.471°,33.261°,33.713°,34.162°,34.891°,35.339°,36.563°,37.236°,38.302°,
40.710°  showing a typical crystalline pattern.
10.1.7. Fourier Transform Infra Red spectrum of Fenofibrate
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Figure 13: FTIR Spectrum of Fenofibrate
Inference: Characteristic  peaks  of  Fenofibrate  were  observed  from  FTIR  peaks  and
summarized in Table 13.
Table 34: FTIR peaks and their functional groups of Fenofibrate
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Functional Group IR range (cm-1) Peak observed (cm-1)
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Usually  O-H carboxylic 3800-3550 3842.12
3782.30
O-H alcoholic 3500-3100 3562
= C-H & = CH2 3020-3100 3031.02
CH3,  CH2 & CH 2850-3000 2990.06
2929.52
2865.20
C-H 2690-2840 2736.39
C=O (saturated aldehyde) 1720-1740 1729.35
C=O (saturated ketone) 1710-1720 1712.53
1710.58
CH2 & CH3 1350-1470 1599.30
1442.98
OH bending 1330-1430 1385.66
1370.31
1359.87
1331.01
C=O 1210-1320 1299.75
1262.05
O-H bonded 970-1250 1245.93
1223.87
C-N 1000-1250 1167.89
O-H bonded 970-1250 1155.96
1126.53
1117.16
1104.27
1074.96
1055.16
1044.76
1013.75
=C-H & = CH2 880-995 991.61
969.25
925.04
=  CH2 780-850 842.41
765.58
10.1.8. Powder and Flow Properties of API
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Table 35: Flow and powder properties of API
Parameters API
Bulk density (gm/ml) 0.208
Tapped density (gm/ml) 0.333
Compressibility Index (CI) % 37.53
Hausner’s ratio (HR) 1.51
Angle of repose (θ) 45
Inference: Flow and powder properties of API were very very poor and may hang up hence
tablets can be prepared by granulation method.
10.1.9. Drug content estimation
Table 36: Drug content in solid dispersions
Formulation code % drug content
Drug 99.86
SD1 98.65
SD2 99.12
SD3 98.01
SD4 98.35
SD5 99.7
SD6 98.5
SD7 99.36
SD8 99.13
SD9 97.89
SD10 99.3
SD11 99.54
SD12 98.63
SD13 99.42
SD14 99.26
SD15 98.92
SD16 98.79
SD17 98.35
SD18 99.6
SD19 99.1
SD20 98.7
SD21 97.8
SD22 99.2
SD23 98.6
SD24 98.1
SD25 99.4
Inference: % drug content in Solid dispersions was found and it is above 97 for all solid
dispersions.
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10.1.1. Solid state characterization of solid dispersion by Differential Scanning 
Calorimetry (DSC)
Figure no: 14 DSC THERMOGRAM OF SD 1 (FENOFIBRATE+PVP K90)
Inference: DSC thermogram of solid dispersion of drug and PVP K90 showing a sharp peak
obtained at 77.080c. This peak indicates the crystalline form of the drug in the dispersion as
the peak is obtained in the melting point range of the drug. 
There  was  no  change  in  the  polymorphic  form  of  the  drug  from  crystalline  form  to
amorphous form. Hence the solid dispersion has not been formed 
Hence this formulation cannot be considered for further studies of solubility.
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Figure no: 15 DSC THERMOGRAM OF SD 2 (FENOFIBRATE + SOLUPLUS)
Inference: 
Dsc thermogram of solid dispersion of drug and soluplus does not show any sharp peak in the
melting point range of the drug (78 to 820c).
This  indicates  that  the  drug  molecular  form has  been  changed  from crystalline  form  to
amorphous form and dispersion is formed between the drug and the polymer.
Hence  this  solid  dispersion  can  be  chosen  for  the  further  solubility  studies  and
characterization through x ray diffraction and other studies.
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Figure no: 16 DSC THERMOGRAM OF SD 3 (FENOFIBRATE + KOLLICOAT IR)
Inference: 
Dsc thermogram of solid dispersion of drug and kollicoat IR showing a sharp peak obtained
at 770c. This peak indicates the crystalline form of the drug in the dispersion as the peak is
obtained in the melting point range of the drug. 
There  was  no  change  in  the  polymorphic  form  of  the  drug  from  crystalline  form  to
amorphous form. Hence the solid dispersion has not been formed 
Hence this formulation cannot be considered for further studies of solubility.
The appearance of the drug peak indicates a poor molecular interaction between the drug and
the polymer
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Figure no: 17 DSC THERMOGRAM OF SD 4 (FENOFIBRATE + HPC SSL)
Inference: 
 DSC thermogram of solid dispersion of drug and HPC SSL showing a sharp peak obtained at
77.610c. This peak indicates the crystalline form of the drug in the dispersion as the peak is
obtained in the melting point range of the drug. 
There  was  no  change  in  the  polymorphic  form  of  the  drug  from  crystalline  form  to
amorphous form. Hence the solid dispersion has not been formed 
Hence this formulation cannot be considered for further studies of solubility.
The appearance of the drug peak indicates a poor molecular interaction between the drug and
the polymer
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Figure no: 18 DSC THERMOGRAM OF SD 5 (FENOFIBRATE + HPMC 3CPS)
Inference:  DSC thermogram of solid dispersion of drug and soluplus does not show any
sharp peak in the melting point range of the drug (78 to 820c).
This  indicates  that  the  drug  molecular  form has  been  changed  from crystalline  form  to
amorphous form and dispersion is formed between the drug and the polymer.
Hence  this  solid  dispersion  can  be  chosen  for  the  further  solubility  studies  and
characterization through x ray diffraction and other studies
Conclusion of DSC studies of solid dispersions SD 1 to SD 5:
From the differential scanning calorimetry studies of the 5 solid dispersions it was concluded
that the solid dispersions SD 2(drug + soluplus) and SD 5(drug + hpmc 3cps) has shown a
change in the polymorphic form of the drug from crystalline to amorphous form.
Hence these two formulations have been chosen for the solubility studies to optimize the ratio
of drug and the polymer
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10.2. Solubility studies
Table no: 37 Solubility studies of solid dispersions SD 6 to SD 15 (fenofibrate + soluplus)
in water
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
Solvent 
evaporation 
method
9.28 µg/ml 29.06 µg/ml 81.02 µg/ml 83.25 µg/ml 88.30 µg/ml
Melt fusion 
method
5.40 µg/ml 18.01 µg/ml 69.08 µg/ml 75.60 µg/ml 81.07 µg/ml
Table no: 38 Solubility studies of solid dispersions (fenofibrate + soluplus) in pH 1.2 
buffer
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
Solvent 
evaporation 
method
12.5 µg/ml 19.6 µg/ml 51.25 µg/ml 71.40.µg/ml 81.07 µg/ml
Melt fusion 
method
4.80 µg/ml 11.1 µg/ml 18.15 µg/ml 33.50 µg/ml 59.82 µg/ml
Table no: 39 Solubility studies of solid dispersions (fenofibrate + soluplus) in pH 4.5 
acetate buffer
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
Solvent 
evaporation 
method
14.46 µg/ml 42.14 µg/ml 62.67 µg/ml 108.21µg/ml 122.5 µg/ml
Melt fusion 
method
9.48 µg/ml 31.1 µg/ml 50.78 µg/ml 81.54 µg/ml 93.57 µg/ml
Table no: 40 Solubility studies of solid dispersions (fenofibrate + soluplus) in pH 6.8 
phosphate buffer
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
110
                                                                               Results and Discussion
Solvent 
evaporation 
method
8.75 µg/ml 25.3 µg/ml 60 µg/ml 85.8 µg/ml 88.57 µg/ml
Melt fusion 
method
6.24 µg/ml 16.42 µg/ml 52.2 µg/ml 78.62 µg/ml 83.75 µg/ml
Inference: Comparative  study  between  the  solubility  of  solid  dispersion  formulated  by
solvent evaporation and melt fusion method is done to optimize the method of preparation of
solid dispersion having maximum solubility
Solubility studies of SD 6 to SD15 in 5 different ratios 1:0.5, 1:1, 1:2, 1:3, 1:4 have been
performed for both solvent evaporation and fusion method of preparation in all the medias
water, pH 1.2 buffer, pH 4.5 acetate buffer, pH 6.8 phosphate buffer.
In all the pH conditions solid dispersion prepared by solvent evaporation method has shown
better solubility compared to solid dispersion prepared by fusion method. 
Solubility of the drug has been enhanced from 0.4 µg/ml to a maximum of 122.5 µg/ml in 4.5
acetate buffer showing a considerable increase in the solubility of the drug in the solid 
dispersion compared to the pure drug.
Table no: 41 Comparision of solubility profile of 1:4 ratio in all pH conditions:
Drug + 
soluplus 1:4
water 1.2 4.5 6.8
Solvent 
evaporation
88.30 µg/ml 81.07 µg/ml 122.5 µg/ml 88.57 µg/ml
Melt fusion 81.07 µg/ml 51.82 µg/ml 93.57 µg/ml 83.75 µg/ml
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Figure no: 19: comparative solubility data of drug + soluplus
Solvent evaporation method can been preferred for the preparation of solid dispersion using
soluplus as it is showing better solubility compared to the solid dispersion prepared by fusion
method.
It can also be noted that there is a change in the solubility of the drug in the solid dispersion
with the change in the pH of the media but solubility of the pure is not influenced by the
change in the pH of the media because of the lack of ionisable groups in the structure.
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10.2.1. Solubility studies of SD 16 to 25:
Table no: 42 Solubility studies of solid dispersions (fenofibrate + HPMC 3cps) in water
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
Solvent
evaporation
method
3.92 µg/ml 4.25 µg/ml 6.07 µg/ml 18.75 µg/ml 19.98 µg/ml
Melt fusion
method
6.23 µg/ml 8.54 µg/ml 11.21 µg/ml 25.53 µg/ml 31.6 µg/ml
Table no: 43 Solubility studies of solid dispersions (fenofibrate + HPMC 3cps) in pH 1.2 
buffer
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
Solvent
evaporation
method
0.714 µg/ml 3.57 µg/ml 6.07 µg/ml 9.28 µg/ml  11.42µg/ml
Melt fusion
method
2.58 µg/ml 6.12 µg/ml 8.06 µg/ml 14.1 µg/ml 21.96 µg/ml
Table no: 44 Solubility studies of solid dispersions (fenofibrate + HPMC 3cps) in pH 4.5 
acetate buffer
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
Solvent 4.28 µg/ml 5.71 µg/ml 8.03 µg/ml 8.57 µg/ml 11.6 µg/ml
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evaporation
method
Melt fusion
method
9.54 µg/ml 11.11 µg/ml 13.24 µg/ml 19.28 µg/ml 30.8 µg/ml
Table no: 45 Solubility studies of solid dispersions (fenofibrate + HPMC 3cps) in pH 6.8 
phosphate buffer
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
Solvent
evaporation
method
1.78 µg/ml 3.57 µg/ml 7.35 µg/ml 9.82 µg/ml 14.1 µg/ml
Melt fusion
method
9.51 µg/ml 14.22 µg/ml 19.67 µg/ml 25.89 µg/ml 40.89 µg/ml
Table no: 46 Solubility studies of solid dispersions (fenofibrate + HPMC 3cps) in pH 7.4 
buffer
Solid
dispersion
Drug : carrier ratio
1:0.5 1:1 1:2 1:3 1:4
Solvent
evaporation
method
3.57 µg/ml 3.75 µg/ml 4.821 µg/ml 10.89 µg/ml 12.32 µg/ml
Melt fusion
method
7.54 µg/ml 11.61 µg/ml 18.14 µg/ml 26 µg/ml 39.28 µg/ml
Inference: Comparative  study  between  the  solubility  of  solid  dispersion  formulated  by
solvent evaporation and melt fusion method is done to optimize the method of preparation of
solid dispersion having maximum solubility
Solubility studies of SD 16 to SD 25 in 5 different ratios 1:0.5, 1:1, 1:2, 1:3, 1:4 have been
performed for both solvent evaporation and fusion method of preparation in all the medias
water, pH 1.2 buffer, pH 4.5 acetate buffer, pH 6.8 phosphate buffer.
In all the pH conditions solid dispersion prepared by melt fusion method has shown better
solubility compared to solid dispersion prepared by solvent evaporation method. 
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Solubility of the drug has been enhanced from 0.4 µg/ml to a maximum of 40.89 µg/ml in pH
6.8 phosphate buffer showing a considerable increase in the solubility of the drug in the solid 
dispersion compared to the pure drug.
Table no: 47 Comparision of solubility profile of 1:4 ratio in all pH conditions:
Drug + HPMC
1:4
Water 1.2 4.5 6.8 7.4
Solvent 
evaporation
19.98 11.42 11.6 14.1 12.32
Melt fusion 31.6 21.96 30.8 40.89 39.28
Figure no: 20 comparative solubility data of drug + HPMC
Melt fusion method can been preferred for the preparation of solid dispersion using HPMC
3cps as it is showing better solubility compared to the solid dispersion prepared by Solvent
evaporation method.
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It can also be noted that there is a change in the solubility of the drug in the solid dispersion
with the change in the pH of the media but solubility of the pure is not influenced by the
change in the pH of the media because of the lack of ionisable groups in the structure.
Conclusion of solubility studies of solid dispersions:
From the solubility studies it can be concluded that the SD 10 (drug + soluplus) has shown
better solubility by solvent evaporation method than the melt fusion method because in the
fusion method the melting range of drug is 78 to 82 0c and the glass transition temperature of
the soluplus is 70oc. Hence polymer changes its form before the drug gets melted. 
Because of formation of sticky mass there was no proper mixing of drug and polymer and
hence the drug molecules can be seen as molecular lumps in the polymer
The drug has not got completely dispersed in the polymer.
In case of SD 25(drug + HPMC 3cps) solid dispersion prepared by melt fusion method has
shown better solubility in all the pH conditions because the melting point of polymer is high
compared to the drug and the glass transition temperature (Tg)of polymer is 170 to 180 oc. 
Hence drug gets melted first and can be uniformly dispersed in the polymer and hence better
stability can also be achieved by melt fusion method.
On the other  hand in solvent evaporation method HPMC forms a viscous solution in the
solvent and hence the drug may not get properly dispersed in the polymer during mixing and
during  evaporation  there  is  an  improper  molecular  interaction  between  the  drug  and  the
polymer.
The solid dispersion ratio of 1:4 has shown better solubility in all the formulations and this
ratio is chosen for the optimized formula. 
The optimized formula of 1:4 ratio of drug and soluplus prepared by solvent evaporation
method and 1:4 ratio of drug and HPMC 3cps prepared by melt fusion method, have been
loaded in the stability chamber (40 oc / 75% RH) for the stability study of the solid dispersion.
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10.3 STABILITY STUDIES
10.3.1 Characterization of SD 10 and SD 25 by Differential scanning calorimetry (DSC)
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Figure no: 21   Comparison of DSC thermogram of initial and stability sample of solid 
dispersion 10 (Fenofibrate + soluplus)
Inference: After stability loading for one month at 40 oc / 75% RH the DSC thermogram of
SD 10 (drug + soluplus) is showing the drug peak at 77 oc where as initial solid dispersion has
not shown any sharp peak.
        It indicates that the drug is re crystallizing from the solid dispersion after exposing to
stability conditions.
Hence formulation is not considered for the further studies due to lack of stability
Figure no: 22 Comparision of DSC thermogram of initial and stability sample of solid 
dispersion 25 (fenofibrate + HPMC 3cps)
Inference: After stability loading for one month at 40 oc / 75% RH the DSC thermogram of 
SD 25 (drug + HPMC 3cps) is not showing any sharp peak and the DSC thermogram is 
similar to the initial thermogram of the solid dispersion
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        It indicates that the drug remained in the amorphous even after exposing to high temperature
and moisture.
Hence this formulation (SD 25) can be considered as optimized formulation because of high
stability can be used for further formulations instead of drug because of better solubility than
the drug and it can be further characterized by XRD and FT IR studies for confirming the
stability of the formulation.
10.3.2. Solid state characterization by X-Ray Diffraction Studies (XRD):
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Figure 23: Overlay of XRD patterns of (a) solid dispersion (b) HPMC (c) PVP K30 (d)
Fenofibrate
Inference: XRD Diffractogram of HPMC showed that the polymer is amorphous in nature.
Pure drug has shown sharp crystalline peaks whereas solid dispersion has converted drug
from crystalline to amorphous state which resulted in improved solubility and dissolution
properties.  Solid  dispersion (SD 25) does  not  show any of  the  characteristic  drug  peaks
indicating the amorphous nature of drug in the solid dispersion.
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Figure no: 24 COMPARITIVE XRD OF DRUG SOLID DISPERSION (INITIAL) AND 
STABILITY SAMPLE OF SOLID DISPERSION (400C & 75%RH) Open Exposure
Inference:  The  x  ray  diffraction  pattern  of  stability  sample  of  solid  dispersion(open
exposure) is similar to initial Diffractogram indicating that the drug has not re crystallized
after open exposure to high temperature and moisture.
Hence x-ray diffraction studies confirm the stability of the solid dispersion formulated by
using HPMC 3cps as polymer.
10.3.3. Investigation of chemical interaction between drug and carrier in solid 
dispersion by FTIR:
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Figure no: 25 FT IR OF SOLID DISPERSION (SD 25) CONTAINING DRUG AND HPMC 
3CPS
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Figure 26: FTIR Spectrum of solid dispersion containing drug and HPMC 3cps and
Fenofibrate
Inference: FTIR spectrum of Fenofibrate is not identical with FTIR spectrum of solid 
dispersion which indicates that there might be drug carrier interaction in solid dispersion 
which resulted in improved solubility of Fenofibrate
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Figure 27: Overlay of FTIR spectrums of solid dispersion containing drug, HPMC, and
Fenofibrate with the stability sample.
Inference: FT IR spectra of solid dispersion before and after exposure to high temperature
and moisture levels are similar showing identical peaks. But the transparency of KBr pellet
making varied which resulted in less depth of the peaks but the wave numbers are identical
indicating that the solid dispersion is stable.
.
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10.4. Preformulation studies of tablet
10.4.1. Physical characterization of solid dispersion.
A).Particle size distribution:
Table 48: Particle size determination of solid dispersion
Sieve
Mesh
Number
Sieve Size
Opening(µm)
Mass of Sample
Retained on Each
Sieve(g)
Percentage of
Sample Retained
on Each Sieve (%)
Cumulative
Percentage of
Sample Retained
on Each Sieve (%)
20 841 0 0 0
40 420 0.02 0.4 0.4
60 250 0.86 17.2 17.6
80 177 1.26 20.2 37.8
100 149 0.49 9.8 47.6
120 125 0.9 13 60.6
Pan - 1.47 49.4 100
Inference:  From the particle size distribution data,  it  was observed that, 49.4 % of  solid
dispersion particles were found to be below of 125 microns in size.
10.4.2. Drug-Excipients compatibility studies:
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Table 49: Visual observation for Solid dispersion-Excipient Ratios for
Compatibility Study
Physical Appearance
Composition
Code
Initial
I Week
40°C/75%
RH
II Weeks,
40°C/75%
RH
III Weeks,
40°C/75%
RH
IV Weeks,
40°C/75%
RH
Solid dispersion
Cream
White
powder
NC NC NC NC
Solid dispersion
+ Mannitol
Cream
White
powder
NC NC NC NC
Solid
dispersion+
lactose
Cream
White
powder
NC NC NC NC
Solid
dispersion+
Sorbitol
Cream
White
powder
NC NC NC NC
Solid
dispersion+
Ppxl
Cream
White
powder
NC NC NC NC
Solid
dispersion+
Mg sterate
Cream
White
powder
NC NC NC NC
       *NC- no change
10.5 DSC THERMOGRAMS OF SOLID DISPERSION - EXCIPIENT
COMPATABILITY STUDY BEFORE AND AFTER EXPOSURE TO ACCELERATED
CONDITIONS
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Figure no:28  DSC of solid dispersion before and after accelerated storage condition (40oC &
75% RH open exposure)
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Figure no:29  DSC of solid dispersion and Mannitol physical mixture before and after
accelerated storage condition (40oC & 75% RH open exposure)
Inference:
DSC theromogram of the physical mixture of solid dispersion and mannitol before and after
exposure to accelerated conditions of storage are similar. It indicates that the drug and the
mannitol are compatible with each other and hence mannitol can be used for the formulation
of ODT with the solid dispersion. 
Thermogram also indicates the stability of the solid dispersion in the amorphous form.
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Figure no:30  DSC of solid dispersion and Sorbitol physical mixture before and after
accelerated storage condition (40oC & 75% RH open exposure)
Inference:
DSC theromogram of the physical mixture of solid dispersion and sorbitol before and after
exposure to accelerated conditions of storage are similar. It indicates that the drug and the
sorbitol are compatible with each other and hence sorbitol can be used for the formulation of
ODT with the solid dispersion. 
Thermogram also indicates the stability of the solid dispersion in the amorphous form.
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Figure no:31  DSC of solid dispersion and Lactose physical mixture before and after
accelerated storage condition (40oC & 75% RH open exposure)
Inference:
DSC theromogram of the physical mixture of solid dispersion and Lactose before and after
exposure to accelerated conditions of storage are similar. It indicates that the drug and the
Lactose are compatible with each other and hence Lactose can be used for the formulation of
ODT with the solid dispersion. 
Thermogram also indicates the stability of the solid dispersion in the amorphous form.
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Figure no:32  DSC of solid dispersion and polyplasdone XL physical mixture before and
after accelerated storage condition (40oC & 75% RH open exposure)
Inference:
DSC theromogram of the physical mixture of solid dispersion and polyplasdone XL before
and after exposure to accelerated conditions of storage are similar. It indicates that the drug
and the polyplasdone XL are compatible with each other and hence polyplasdone XL can be
used for the formulation of ODT with the solid dispersion. 
Thermogram also indicates the stability of the solid dispersion in the amorphous form.
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Figure no:33  DSC of solid dispersion and Magnesium stearate physical mixture before and
after accelerated storage condition (40oC & 75% RH open exposure)
Inference:
DSC theromogram of the physical mixture of solid dispersion and Magnesium stearate before
and after exposure to accelerated conditions of storage are similar. It indicates that the drug
and the Magnesium stearate are compatible with each other and hence Magnesium stearate
can be used for the formulation of ODT with the solid dispersion. 
Thermogram also indicates the stability of the solid dispersion in the amorphous form.
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10.6 EVALUATION PARAMETERS
10.6.1 Blend Characterization
Table 50: Blend characterization of formulations of trial batches
Formula
tion
Code
Tapped
Density
(gm/cm3)
bulk
density
(gm/cm3)
Compressibility
Index (CI) (%)
Hausner
ratio
(HR)
Angle
of
repose
(θ)
PSD (in
µ)
F1 0.36 0.33 9.09 1.09 26.2 11-12
F2 0.37 0.34 8.11 1.09 25.7 12-13
F3 0.39 0.35 10.25 1.11 33.5 11-12
F4 0.36 0.32 11.11 1.13 31.7 11-12
F5 0.34 0.31 8.82 1.10 28.4 13-14
F6 0.36 0.31 13.88 1.16 24.8 12-13
Inference: 
The granules prepared for compression of tablets were evaluated for their flow properties; the
results for the blends of compression tablets were shown in Table-49.
The formulations showed good flow property and Carr’s index. Angle of repose ranged from
24.70 to 33.50 and the Carr’s index ranged from 9.09 to 13.88. The Bulk Density and Tapped
Bulk Density of the prepared granules ranged from 0.3 to 0.354g/cc and 0.33 to 0.39 g/cc
respectively. The results of angle of repose indicates good flow property of the granules and
the value of Carr’s compressibility index further showed support for the flow property.
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   10.6.2 EVALUATION OF ORAL DISINTEGRATING TABLETS
Table 51: Physical parameters of tablets of trial batches
Table 52 Physicochemical parameters of oral disintegrating tablets of trial batches
Inference:  The  variation  in weight was within  the  range  of  ±7.5%  complying with
pharmacopoeial  specifications . The thickness of tablets was found to be between 4-5 mm.
The  friability was below 1%  for  all  the  formulations, which  is  an  indication  of  good
mechanical  resistance  of  the  tablet.   
The  percentage  drug  content  varied  between  97  to  99.37%  in  different  formulations
indicating content uniformity in the prepared batches
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Formulation
code
Target
weight
(mg)
Weight
variation
(%)
Thickness
(mm)
Friability
(%)
F1 350 + 1.68 4.11+ 0.2 0.72 + 0.03
F2 350 + 1.37 4.09+ 0.1 0.67 + 0.09
F3 350 + 0.51 4.11+ 0.1 0.74 + 0.03
F4 350 + 0.49 4.12+ 0.1 0.65 + 0.02
F5 350 + 0.55 3.08+ 0.3 0.76 + 0.12
F6 350 + 1.68 4.11+ 0.2 0.84 + 0.02
Formulation
code
% drug content
F1 98.74 + 0.42
F2 97.12 + 0.63
F3 99.37 + 0.51
F4 96.21 + 0.23
F5 98.28 + 0.36
F6 96.37 + 0.45
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10.7  EFFECT  OF  MOISTURE  TREATMENT  ON  HARDNESS  AND
DISINTEGRATION TIME OF THE FORMULATIONS
10.7.1 Effect of  formulation hardness on the disintegration time of  the tablet  before
moisture treatment:
Formulation Hardness 1 to 2 kp Hardness 2 to 3 kp
F1 1 min 54sec 3 min 58sec
F2 1 min 30sec 3 min 21sec
F3 1 min 42sec 3 min 28sec
F4 26sec 1 min 10sec
F5 20sec 45sec
F6 14sec 30sec
Table 53: Effect of formulation hardness on the disintegration time
10.7.2 Effect of moisture treatment on Hardness:
Moisture exposed Hardness
33%RH Increased up to 2 kp
53%RH No effect on hardness
84%RH Softening of tablet, hardness below 1 kp
Table 54: Effect of moisture treatment on Hardness
10.7.3 Effect of moisture treatment on Disintegration time:
Moisture exposed Disintegration time
33%RH Increased from 1 min to 2 min
53%RH Decreased from 3 min to 2 min 20sec
84%RH Very less 4 to 5sec
Table 55: Effect of moisture treatment on DT
Inference:
Based on the results obtained after moisture treatment it was found that 
1.  When  exposed  to  low  moisture  condition  (33%RH)  tablets  hardness  is  considerably
increased (up to 2kp) and disintegration time also increased because of increased hardness.
The reason for increased hardness  is  that  at  low moisture levels  tablets  absorb sufficient
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moisture to form liquid bridges that will be converted to solid bridges between the molecules
on drying that led to the increase in the hardness and as a result DT is also increased.
2. When exposed to optimum moisture condition (53%RH) hardness has no influence on the
hardness of the tablet and DT decreased. 
3. When exposed to high moisture condition (84%RH) tablets got softened and DT was very
low because of softening. The reason for softening was due to formation of too many liquid
bridges between the molecules because of high moisture levels. Even on drying the tablets
hardness was not increased. 
The amount of super disintegrant in the formulation also influences the hardness and DT
during the moisture treatment.
Amount of super disintegrant for the optimized formulation was chosen as 5mg/tab because
high amount of super disintegrant may lead to softening of tablet on moisture treatment.
Hence the optimized formulation is chosen as the one containing 
Hardness – 2- 3 KP
Moisture treatment - 53%RH
DT – 20 to 30 sec
Because at 2 to 3kp the tablets will be sufficiently hard for blister packing and bottle packing
also. Moisture exposure to 53%RH may not affect the hardness but DT will be sufficiently
lowered because of formation of liquid bridges. The amount of super disintegrant was chosen
as 5mg/tab to enhance the disintegration of the tablet. 
Optimized  formulation  (F4)  based  on  Hardness,  Disintegration  time,  and  Moisture
treatment:
Ingredients Amount (mg/tab)
Solid dispersion 160
Mannitol 162
Sorbitol 18
Polyplasdone XL 5
Magnesium stearate 5
136
                                                                               Results and Discussion
Ethanol q.s
Total 350
Table no: 56 Optimum formula
Parameters of optimized formulation before and after Moisture treatment (53%) RH:
Evaluated parameters Before moisture treatment After Moisture treatment
Weight of tablet 350mg 353mg
Hardness 2 to 2.5 kp 2 to 3 kp
Disintegration time 56sec 28sec
Table no: 57 Effect of moisture treatment
10.8 In vitro dissolution studies: 
10.8.1 In vitro drug release from formulation f2 and f3 in 0.5%sls in water media
Time (min)
% drug release
F2 F3
5 65.1 61.1
10 72 68.4
15 91.1 90.8
30 99.4 99.2
137
                                                                               Results and Discussion
45 99.5 99.4
60 99.3 99.5
Table 58: In vitro drug release
Figure no: 34  
Inference:
The %drug release was not that influenced by Mannitol or Lactose. Although there was an 
slight initial lag in release of drug on use of lactose than use of Mannitol. Hence Mannitol 
was chosen for further formulations as the final drug release percentage was same. 
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10.8.2 Comparision of In vitro dissolution studies of optimized formulation and pure 
drug   in Different pH conditions:
Table 59:  Dissolution profile in pH 1.2 buffer
Figure no: 35
10.8.3 Dissolution profile in pH 4.5 buffer
Table 60: In vitro drug release in 4.5
buffer
Figure no: 36
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Time
(min)
Fenofibrate
tablet
Optimized
formulation
5
6.8 11.65
10
7.2 17.52
15
8.43 21.22
30
8.44 24.7
45
8.41 26.8
60
8.52 26.9
Time
(min)
Fenofibrate
tablet
Optimized
formulation
5
5.2 13.2
10
6.1 16.8
15
6.8 18.2
30
6.9 26.7
45
6.7 30.4
60
6.4 30.2
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10.8.4 Dissolution profile in pH 6.8 buffer
Table 61: In vitro drug release in 6.8 
medium
Figure no:37
Inference:
The amount of drug release from the solid dispersion in optimized formulation was higher in
all pH conditions compared to the pure drug in the formulation. The release rate was found to
42% at the end of 45 min in 6.8 phosphate buffer while the pure drug has shown only 7.6% of
release.
The drug release was found to be stabilized after certain time points indicating that the max
solubility (saturation solubility) of the drug in the medium has been reached. 
The  release  profile  of  the  drug  has  been  significantly enhanced  by formulating  as  solid
dispersion than that of pure drug.
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Time
(min)
Fenofibrate
tablet
Optimized
formulation
5
4.1 16.5
10
         4.8 21.7
15
6.2 27.4
30
7.1 36.1
45
7.5 42.5
60
7.6 42.1
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10.8.5 Dissolution profile in 0.5% sls in water
Table 62: In vitro drug release from 
dissolution medium
Figure no: 38
Inference:
The optimized formulation has shown 99% drug release from the solid dispersion at the end
of 30mins compared to only 61% of drug release from the pure drug formulation at the end of
60mins. 
Hence the drug release will be better by using drug as solid dispersion rather than using drug
as such in the formulation for the hyper lipidemic patients.
10.9 Accelerated Stability study of the optimized batch 
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Time
(min)
Fenofibrate
tablet
Optimized
formulation
2 14.8 64.2
5
40.17 67.9
10
       48.61 71.4
15
       52.7 92.4
30
55.84 99.8
45
57.05 99.9
60
61.4 99.7
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Figure no: 39
Table 63: Stability studies at 400C and 75%RH
PARAMETER Initial 30th Day
COLOUR White No change
WEIGHT 350+/-5 mg 350+/-5mg
ASSAY 99% 98.1%
% RELEASE 98.9% at end of 45 min 97.6% at end of 45 min
Table 64: Stability studies at 250C and 60%RH
PARAMETER Initial 30th Day
COLOUR White No change
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WEIGHT 350+/-5 mg 350+/-5mg
ASSAY 99.2% 98.1%
% RELEASE 99% at end of 45 min 97.9% at end of 45 min
Inference:
There was no drug peak even after the exposure of the final tablet to accelerated conditions of
temperature and humidity. Hence the final formulation is found to be stable
 The tablet has been stable even after exposure to accelerated condition
Assay and percentage release even after exposure to accelerated conditions are with in the
limits indicating stability of formulation
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XI. SUMMARY AND CONCLUSION
The main aim of present study is to develop a rapidly dissolving tablet of Anti hyperlipidemic
drug  using  saccharides  for  better  mouth  feel  and  improving  patient  compliance.  The
solubility of pure drug is very low in all the pH conditions hence in order to improve the
solubility drug is converted in to solid dispersion.
Solid dispersion’s are prepared by using polymers PVP K90, soluplus, kollicoat IR, HPC SSL
and HPMC 3cps by solvent evaporation method. Out of 5 polymers only soluplus and HPMC
has shown a change in the crystalline nature of the drug to amorphous form as indicated by
the DSC thermogram
Hence solid dispersion prepared by using soluplus and HPMC in various ratios 1:0.5, 1:1,
1:2, 1:3, 1:4 by both solvent evaporation and melt fusion method to find the effect of method
of preparation on the solubility enhancement.
Solvent evaporation method has produced better solubility in the case of soluplus but the
formulation has failed in the stability studies showing drug peak in the DSC thermogram. On
the  other  hand  with  HPMC  melt  fusion  method  has  shown  better  solubility  and  the
formulation is found to be stable as shown by the DSC, XRD and FTIR studies. Hence drug
and  HPMC in  1:4 ratio  formulated  by melt  fusion  method is  chosen  as  optimized  solid
dispersion
By using optimized solid dispersion oral disintegrating tablets of 6 formulations have been
prepared  to  optimize  the  concentration  of  super  disintegrant  needed  to  attain  the  desired
disintegration time. Tablets compressed at two different hardness levels 1-2 kp and 2-3 kp are
exposed to 3 different  moisture conditions  (33%, 53%, 84%RH) to optimize the level  of
moisture needed for attaining sufficient hardness and DT.
53%RH was found to be optimum that slightly increases the hardness and lowers the DT
below 30sec with 5mg/tab of super disintegrant compressed at 2 KP hardness.
The drug release from the optimized formulation was compared with that of the pure drug in
all pH conditions and is found to be better from the solid dispersion rather than the pure drug.
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Optimized formula has shown a release of 99% at the end of 30mins where as release from
pure drug formulation is only 60% at the end of 60min.
Formulation  of  ODT  by  WOWTAB  technology  using  solid  dispersion  technique  has
produced better drug release and good mouth feel and can enhance the patient compliance of
geriatric and pediatric hyperlipidemic patients.   
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